EP3816158A1 - Benzimidazole derivatives and use thereof as idh1 inhibitors - Google Patents
Benzimidazole derivatives and use thereof as idh1 inhibitors Download PDFInfo
- Publication number
- EP3816158A1 EP3816158A1 EP19827510.9A EP19827510A EP3816158A1 EP 3816158 A1 EP3816158 A1 EP 3816158A1 EP 19827510 A EP19827510 A EP 19827510A EP 3816158 A1 EP3816158 A1 EP 3816158A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mmol
- added
- solution
- stirred
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 4
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims abstract description 32
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims abstract description 24
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims abstract description 24
- -1 cyclopropanyl Chemical group 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 4
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical group F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 251
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 100
- 239000000243 solution Substances 0.000 description 92
- 235000019439 ethyl acetate Nutrition 0.000 description 84
- 239000000203 mixture Substances 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 23
- 239000012267 brine Substances 0.000 description 21
- 239000012043 crude product Substances 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 0 CC(*)c1c(*)cccc1 Chemical compound CC(*)c1c(*)cccc1 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
- HWXBTNAVRSUOJR-UHFFFAOYSA-L 2-hydroxyglutarate(2-) Chemical compound [O-]C(=O)C(O)CCC([O-])=O HWXBTNAVRSUOJR-UHFFFAOYSA-L 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229910000033 sodium borohydride Inorganic materials 0.000 description 16
- 239000012279 sodium borohydride Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
- YQWIWXOIMLZUJQ-HWKANZROSA-N methyl (E)-3-(4-fluoro-3-nitrophenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(F)C([N+]([O-])=O)=C1 YQWIWXOIMLZUJQ-HWKANZROSA-N 0.000 description 14
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 11
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- JKSZUQPHKOPVHF-UHFFFAOYSA-N 1-isothiocyanato-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(N=C=S)C=C1 JKSZUQPHKOPVHF-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229910052681 coesite Inorganic materials 0.000 description 7
- 229910052906 cristobalite Inorganic materials 0.000 description 7
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 229910052682 stishovite Inorganic materials 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 229910052905 tridymite Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102200069690 rs121913500 Human genes 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 102200069708 rs121913499 Human genes 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- RNMAUIMMNAHKQR-QFBILLFUSA-N 3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid Chemical compound FC(OC1=CC=C(C=C1)NC1=NC2=C(N1[C@H]1CC(C[C@H](C1)C)(C)C)C=CC(=C2)CCC(=O)O)(F)F RNMAUIMMNAHKQR-QFBILLFUSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 2
- DYFFAVRFJWYYQO-UHFFFAOYSA-N n-methyl-n-phenylaniline Chemical compound C=1C=CC=CC=1N(C)C1=CC=CC=C1 DYFFAVRFJWYYQO-UHFFFAOYSA-N 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- JRZGPXSSNPTNMA-SNVBAGLBSA-N (1r)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2[C@H](N)CCCC2=C1 JRZGPXSSNPTNMA-SNVBAGLBSA-N 0.000 description 1
- VENQOHAPVLVQKV-SSDOTTSWSA-N (1r)-1-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1[C@@H](C)N VENQOHAPVLVQKV-SSDOTTSWSA-N 0.000 description 1
- DQEYVZASLGNODG-ZCFIWIBFSA-N (1r)-1-(3-chlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Cl)=C1 DQEYVZASLGNODG-ZCFIWIBFSA-N 0.000 description 1
- PINPOEWMCLFRRB-ZCFIWIBFSA-N (1r)-1-(4-chlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Cl)C=C1 PINPOEWMCLFRRB-ZCFIWIBFSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-ZCFIWIBFSA-N (1r)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-ZCFIWIBFSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- HWXBTNAVRSUOJR-GSVOUGTGSA-N (R)-2-hydroxyglutaric acid Chemical compound OC(=O)[C@H](O)CCC(O)=O HWXBTNAVRSUOJR-GSVOUGTGSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- PIWPKDUAZFHHNA-UHFFFAOYSA-N 1-isocyanatosulfanyl-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)Oc1ccc(SN=C=O)cc1 PIWPKDUAZFHHNA-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- QWZAOSKLFKAEOK-UHFFFAOYSA-N 3,3-dimethyl-2h-inden-1-one Chemical compound C1=CC=C2C(C)(C)CC(=O)C2=C1 QWZAOSKLFKAEOK-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JLLVOHPMZWUAQU-CNCDYAKUSA-O C/C(/c1ccccc1Cl)=[N+]1/C(Nc(cc2)ccc2OC(F)(F)F)=NC2=CC(CCC(O)=O)CC=C12 Chemical compound C/C(/c1ccccc1Cl)=[N+]1/C(Nc(cc2)ccc2OC(F)(F)F)=NC2=CC(CCC(O)=O)CC=C12 JLLVOHPMZWUAQU-CNCDYAKUSA-O 0.000 description 1
- TUIGROLNLQGIJQ-UHFFFAOYSA-N CC(C(c1ccccc1)I)c1ccc(C(C(F)(F)F)[IH]C)cc1 Chemical compound CC(C(c1ccccc1)I)c1ccc(C(C(F)(F)F)[IH]C)cc1 TUIGROLNLQGIJQ-UHFFFAOYSA-N 0.000 description 1
- WLMSOAXWQKVMOD-VWLOTQADSA-N CC(C)(C)[C@H](c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 Chemical compound CC(C)(C)[C@H](c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 WLMSOAXWQKVMOD-VWLOTQADSA-N 0.000 description 1
- STIQPPZEZYWLNX-QCUIPMNBSA-N CC(C)(C)[S@@](/N=C1/c2ccccc2C(C)(C)C1)=O Chemical compound CC(C)(C)[S@@](/N=C1/c2ccccc2C(C)(C)C1)=O STIQPPZEZYWLNX-QCUIPMNBSA-N 0.000 description 1
- YWCFSEKBXLAJDU-UHFFFAOYSA-O CC(c(cccc1)c1OC)[NH+]1C(Nc(cc2)ccc2[O](C)C(F)(F)F)=Nc2c1ccc(CCC(O)=O)c2 Chemical compound CC(c(cccc1)c1OC)[NH+]1C(Nc(cc2)ccc2[O](C)C(F)(F)F)=Nc2c1ccc(CCC(O)=O)c2 YWCFSEKBXLAJDU-UHFFFAOYSA-O 0.000 description 1
- QAXAFGWHKFGSOG-UHFFFAOYSA-N CCC(c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 Chemical compound CCC(c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 QAXAFGWHKFGSOG-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- QAXAFGWHKFGSOG-JOCHJYFZSA-N CC[C@H](c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 Chemical compound CC[C@H](c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 QAXAFGWHKFGSOG-JOCHJYFZSA-N 0.000 description 1
- CVGAWKYSRYXQOI-UHFFFAOYSA-N CCc(cccc1)c1Cl Chemical compound CCc(cccc1)c1Cl CVGAWKYSRYXQOI-UHFFFAOYSA-N 0.000 description 1
- LDRRMKMORIIACJ-QHCPKHFHSA-N COC(CCc(cc1)cc2c1[n]([C@@H](CC(F)(F)F)c1ccccc1)c(Nc(cc1)ccc1OC(F)(F)F)n2)=O Chemical compound COC(CCc(cc1)cc2c1[n]([C@@H](CC(F)(F)F)c1ccccc1)c(Nc(cc1)ccc1OC(F)(F)F)n2)=O LDRRMKMORIIACJ-QHCPKHFHSA-N 0.000 description 1
- LDRRMKMORIIACJ-HSZRJFAPSA-N COC(CCc(cc1)cc2c1[n]([C@H](CC(F)(F)F)c1ccccc1)c(Nc(cc1)ccc1OC(F)(F)F)n2)=O Chemical compound COC(CCc(cc1)cc2c1[n]([C@H](CC(F)(F)F)c1ccccc1)c(Nc(cc1)ccc1OC(F)(F)F)n2)=O LDRRMKMORIIACJ-HSZRJFAPSA-N 0.000 description 1
- HDNMDORPFQGTPO-HNNXBMFYSA-N C[C@@H](c(cc1)ccc1F)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2cc(CCC(O)=O)ccc12 Chemical compound C[C@@H](c(cc1)ccc1F)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2cc(CCC(O)=O)ccc12 HDNMDORPFQGTPO-HNNXBMFYSA-N 0.000 description 1
- FYMJLPKNAQICJP-LHJMJDNXSA-N C[C@H](c(cc1)ccc1Cl)Nc(ccc(/C=C/C(OC)=O)c1)c1[N+]([O-])=O Chemical compound C[C@H](c(cc1)ccc1Cl)Nc(ccc(/C=C/C(OC)=O)c1)c1[N+]([O-])=O FYMJLPKNAQICJP-LHJMJDNXSA-N 0.000 description 1
- UZIIVEODQCHNCN-OAHLLOKOSA-N C[C@H](c(cc1)ccc1Cl)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 Chemical compound C[C@H](c(cc1)ccc1Cl)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(O)=O)c2 UZIIVEODQCHNCN-OAHLLOKOSA-N 0.000 description 1
- HSPUBUFELMIDCH-QGZVFWFLSA-N C[C@H](c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(OC)=O)c2 Chemical compound C[C@H](c1ccccc1)[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(CCC(OC)=O)c2 HSPUBUFELMIDCH-QGZVFWFLSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- VZZURXLJFFGUFC-UHFFFAOYSA-N FC(C[IH]c1ccccc1)(F)F Chemical compound FC(C[IH]c1ccccc1)(F)F VZZURXLJFFGUFC-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- FWJCUGLOIWJNBX-VWLOTQADSA-N OC(CCc(cc1)cc2c1[n]([C@H](C1CC1)c1ccccc1)c(Nc(cc1)ccc1OC(F)(F)F)n2)=O Chemical compound OC(CCc(cc1)cc2c1[n]([C@H](C1CC1)c1ccccc1)c(Nc(cc1)ccc1OC(F)(F)F)n2)=O FWJCUGLOIWJNBX-VWLOTQADSA-N 0.000 description 1
- QCVZNUSBJIKVOV-UHFFFAOYSA-N OC(CCc1ccc2[nH]c(Nc(cc3)ccc3OC(F)(F)F)nc2c1)=O Chemical compound OC(CCc1ccc2[nH]c(Nc(cc3)ccc3OC(F)(F)F)nc2c1)=O QCVZNUSBJIKVOV-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
Definitions
- the present disclosure relates to a series of benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof.
- Isocitrate dehydrogenase is an important enzyme in the citric acid cycle, and catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate (i.e. 2- ⁇ -ketoglutarate, ⁇ -KG).
- the protein encoded by the IDH 1 gene is NADP(+)-dependent isocitrate dehydrogenase comprising a PTS-1 peroxidase targeting signal sequence found in the cytoplasm and peroxisomes. The presence of this enzyme in peroxisomes suggests a role for internal NADPH regeneration.
- Non-mutant enzyme such as wild-type IDH, catalyzes the oxidative decarboxylation of isocitrate while reducing NAD + (NADP + ) to NADP (NADPH): Isocitrate + NAD + NADP 3 ⁇ ⁇ -KG + CO 2 + NADP NADPH + H +
- IDH 1/2 mutant protein (IDH 1/2 m) has been found in a variety of tumors, including glioma, acute myeloid leukemia (AML), chondrosarcoma, intrahepatic cholangioma, melanoma, prostate cancer, angioimmunoblastic T cell lymphoma.
- AML acute myeloid leukemia
- chondrosarcoma intrahepatic cholangioma
- melanoma prostate cancer
- angioimmunoblastic T cell lymphoma In gliomas, more than 70% of non-primary glioblastomas have IDH1 mutations, and 92.7% of IDH1 mutant tumors have arginine replaced by histidine (i.e. IDH1 R132H) ( Hartmann C, Acta Neuropathol. 2009 Oct;1 18(4):469-74 ).
- the IDH mutant protein has a new function, that is, it catalyzes the reduction of ⁇ -KG to produce a carcinogenic metabolite 2-hydroxyglutarate (2-HG).
- the production of 2-HG is believed to contribute to the formation and development of cancer ( Dang L , Nature, 2009 Dec 10;462(7274):739-44 ).
- Normal cells produce very low levels of 2-HG, but cells with IDH mutations are able to produce high levels of 2-HG. High levels of 2-HG can also be found in tumors with IDH mutations.
- the inhibition of mutant IDH and the new activity thereof is a potential method for cancer treatment. Therefore, there is a need to obtain inhibitors of IDH mutants to inhibit the production of 2-HG.
- Acta Neuropathol (2017, Vol(133), Issue 4, 629-644 ) discloses the specific structure of compound BAY1436032.
- R 1 is selected from C 1-3 alkyl, cyclopropanyl and phenyl, the C 1-3 alkyl, cyclopropanyl and phenyl being optionally substituted with 1, 2 or 3 R a , and other variables are as defined in the present disclosure.
- R 1 is selected from CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , C(CH 3 ) 3 , CH(CH 3 ) 2 and and other variables are as defined in the present disclosure.
- R 2 and R 3 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, C 1-3 alkyl and C 1-3 alkoxy, the C 1-3 alkyl and C 1-3 alkoxy being optionally substituted with 1, 2 or 3 R b , and other variables are as defined in the present disclosure.
- R 2 and R 3 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, CH 3 and CH 3 O, the CH 3 and CH 3 O being optionally substituted with 1, 2 or 3 R b , and other variables are as defined in the present disclosure.
- R 2 and R 3 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, CH 3 , CH 2 F, CHF 2 , CF 3 and OCH 3 , and other variables are as defined in the present disclosure.
- the above-mentioned L is selected from -CH 2 CH 2 - and and other variables are as defined in the present disclosure.
- the above structural unit is selected from and other variables are as defined in the present disclosure.
- the above structural unit is selected from and other variables are as defined in the present disclosure.
- the above structural unit is selected from and other variables are as defined in the present disclosure.
- the above structural unit is selected from and other variables are as defined in the present disclosure.
- the above-mentioned compound, or an isomer thereof, or a pharmaceutically acceptable salt thereof is selected from wherein
- the above-mentioned compound, or an isomer thereof, or a pharmaceutically acceptable salt thereof is selected from wherein E, L, R 1 , R 2 and R 3 are as defined in the present disclosure.
- the present disclosure also provides the compound as shown in the following formula, or an isomer thereof, or a pharmaceutically acceptable salt thereof, which is selected from
- the above-mentioned compound is selected from
- the present disclosure also provides use of the above-mentioned compound, or an isomer thereof, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease related to IDH1.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms that within the scope of reliable medical judgment are suitable for contacting with human and animal tissues, without excessive toxicity, irritation, allergic reactions or other problems or complications, and that are commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salt refers to a salt of the compound of the present disclosure, which is prepared from a compound with specific substituents discovered in the present disclosure and a relatively non-toxic acid or base.
- a base addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of base in a pure solution or a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salt or similar salts.
- an acid addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of acid in a pure solution or a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloride, hydrobromide, nitrate, carbonate, bicarbonate, phosphate, monohydrogen phosphate, dihydrogen phosphate, sulfate, hydrogen sulfate, hydroiodide, phosphite, etc.; as well as organic acid salts, wherein the organic acid includes, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, octanedioic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluene sulfonic acid, citric acid, tartaric acid and methanesulfonic acid, etc.; and also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid.
- the pharmaceutically acceptable salt of the present disclosure can be synthesized from the parent compound containing an acidic or basic functional group by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with stoichiometric amounts of appropriate bases or acids in water or organic solvents or a mixture of both.
- the compounds of the present disclosure may exist in specific geometric or isomeric forms.
- the present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and the racemic mixture and other mixtures thereof, such as enantiomers or diastereomeric enriched mixtures, which are all within the scope of the present disclosure.
- Additional asymmetric carbon atoms may be present in a substituent, such as alkyl. All these isomers and their mixtures are included in the scope of the present disclosure.
- the term “enantiomer” or “optical isomer” refers to isomers that are mirror images of each other.
- cis-trans isomer or “geometric isomer” is caused by the inability to rotate freely because of double bonds or single bonds of ring-forming carbon atoms.
- diastereomer refers to stereoisomers which have two or more chiral centers and the molecules are non-mirror-image relationship.
- the wedge-shaped solid line ( ) and the wedge-shaped dashed line ( ) are used to indicate the absolute configuration of a stereocenter
- the straight solid line ( ) and the straight dashed line ( ) are used to indicate the relative configuration of a stereocenter
- the wavy line ( ) is used to indicate a wedge-shaped solid line ( ) or a wedge-shaped dashed line ( )
- the wavy line ( ) is used to indicate a straight solid line ( ) and a straight dashed line ( ).
- the following formula (A) means that the compound exists as a single isomer of formula (A-1) or formula (A-2) or as a mixture of the two isomers of formula (A-1) and formula (A-2).
- the following formula (B) means that the compound exists as a single isomer of formula (B-1) or formula (B-2) or as a mixture of the two isomers of formula (B-1) and formula (B-2).
- the following formula (C) represents that the compound exists as a single isomer of formula (C-1) or formula (C-2) or as a mixture of the two isomers of formula (C-1) and formula (C-2).
- tautomer or “tautomeric form” means that at room temperature, the isomers with different functional groups are in dynamic equilibrium and can be transformed into each other quickly. If tautomers are possible (such as in a solution), the chemical equilibrium of the tautomers can be reached.
- proton tautomer also referred to as prototropic tautomer, includes interconversion through proton migration, such as keto-enol isomerization and imine-enamine isomerization.
- Valence tautomer includes some recombination of bonding electrons for mutual transformation.
- keto-enol tautomerization is the tautomerism between two tautomers pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
- the terms “enriched in one isomer”, “isomer enrichment”, “enriched in one enantiomer” or “enantiomeric enrichment” means that the content of one isomer or enantiomer is less than 100%, and the content of the isomer or enantiomer is 60% or greater, or 70% or greater, or 80% or greater, or 90 % or greater, or 95% or greater, or 96% or greater, or 97% or greater, or 98% or greater, or 99% or greater, or 99.5% or greater, or 99.6% or greater, or 99.7% or greater, or 99.8% or greater, or 99.9% or greater.
- the term “isomer excess” or “enantiomeric excess” refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80% .
- optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques.
- an enantiomer of a compound of the present disclosure it can be prepared by asymmetric synthesis or derivatization with chiral auxiliary agents, in which the resulting mixture of diastereomers is separated, and the auxiliary group is cleaved to provide the pure desired enantiomer.
- the molecule when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), it can form diastereomeric salts with appropriate optically active acids or bases, and then diastereomers can be resolved by conventional methods known in the art to recover the pure enantiomers.
- the separation of enantiomers and diastereomers is usually accomplished through the use of chromatography, which employs a chiral stationary phase and is optionally combined with chemical derivatization (for example, carbamate is generated from an amine).
- the compounds of the present disclosure may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound.
- compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- deuterated drugs can be formed by replacing hydrogen with deuterium. The bond between deuterium and carbon is stronger than that of ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have reduced toxic side effects and increased drug stability, enhanced efficacy, extend biological half-life and other advantages. All changes in the isotopic composition of the compounds of the present disclosure, whether radioactive or not, are included in the scope of the present disclosure.
- substituted means that any one or more hydrogen atoms on a specific atom are replaced by substituents, including deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the substituted compound is stable.
- Oxygen substitution does not occur on aromatic groups.
- optionally substituted means that the group may be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrary on the basis that they can be chemically realized.
- any variable such as R
- its definition in each case is independent.
- the group can optionally be substituted with up to two Rs, and in each case R is selected independently.
- substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- a substituent When a substituent is vacant, it means that the substituent is absent. For example, when X in A-X is vacant, it means that the structure is actually A.
- substituents can be bonded at any atom.
- the pyridyl group as a substituent can be connected to the substituted group through any carbon atom on the pyridine ring.
- connection direction is arbitrary.
- linking group L in is -M-W-
- -M-W- can connect ring A and ring B in the same direction as the reading order from left to right to form and can also connect ring A and ring B in the opposite direction to the reading order from left to right to form
- Combinations of the linking groups, substituents, and/or variants thereof are only permitted if such combinations result in stable compounds.
- C 1-6 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 6 carbon atoms.
- the C 1-6 alkyl group includes C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 and C 5 alkyl groups, etc.; and can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methyne).
- C 1-6 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n -propyl and isopropyl), butyl (including n -butyl, isobutyl, s -butyl and t -butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl, etc.
- C 1-3 alkyl is used to denote a linear or branched saturated hydrocarbon group composed of 1 to 3 carbon atoms.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; and can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine).
- Examples of C 1-3 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n -propyl and isopropyl), and the like.
- C 1-6 alkoxy refers to an alkyl group containing 1 to 6 carbon atoms that is attached to the rest of the molecule through an oxygen atom.
- the C 1-6 alkoxy group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 alkoxy, etc.
- C 1-6 alkoxy examples include but are not limited to methoxy, ethoxy, propoxy (including n -propoxy and isopropoxy), butoxy (including n -butoxy, isobutoxy, s -butoxy and t -butoxy), pentoxy (including n -pentoxy, isopentoxy and neopentoxy), hexoxy and the like.
- C 1-3 alkoxy refers to an alkyl group containing 1 to 3 carbon atoms that are attached to the rest of the molecule through an oxygen atom.
- the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy groups, etc.
- Examples of C 1-3 alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n -propoxy and isopropoxy) and the like.
- C 3-6 cycloalkyl means a saturated cyclic hydrocarbon group composed of 3 to 6 carbon atoms, which is a monocyclic and bicyclic ring system.
- the C 3-6 cycloalkyl includes C 3-5 , C 4-5 and C 5-6 cycloalkyl, etc.; and can be monovalent, divalent or multivalent.
- Examples of C 3-6 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- C 4-6 cycloalkenyl means a partially unsaturated cyclic hydrocarbon group composed of 4 to 6 carbon atoms containing at least one carbon-carbon double bond, which is monocyclic and bicyclic systems, wherein the bicyclic system includes spiro ring, fused ring and bridged ring, in which each ring is non-aromatic.
- the C 4-6 cycloalkenyl group includes a C 4-5 or C 5-6 cycloalkenyl group, etc.; and may be monovalent, divalent or multivalent.
- C 4-6 cycloalkenyl examples include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
- C 6-12 aromatic ring and “C 6-12 aryl” can be used interchangeably herein.
- the term “C 6-12 aromatic ring” or “C 6-12 aryl” means a cyclic hydrocarbon group composed of 6 to 12 carbon atoms with a conjugated ⁇ -electron system, which can be a single ring, a fused bicyclic ring or condensed tricyclic ring system in which each ring is aromatic. It can be monovalent, divalent or multivalent.
- C 6-12 aryl groups include C 6-10 , C 6-9 , C 6-8 , C 12 , C 10 , and C 6 aryl groups. Examples of C 6-12 aryl groups include, but are not limited to, phenyl, naphthyl (including 1-naphthyl, 2-naphthyl, etc.).
- C n-n+m or C n -C n+m includes any specific case of n to n+m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , including any range from n to n+m, for example, C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.
- n-membered to n+m-membered means that the number of atoms in the ring is from n to n+m
- a 3-12-membered ring includes a 3-membered ring , 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring, 9-membered ring, 10-membered ring, 11-membered ring, and 12-membered ring, including any range from n to n+m, for example, 3-12 membered ring includes 3-6 membered ring, 3-9 membered ring, 5-6 membered ring, 5-7 membered ring, 6-7 membered ring, 6-8 membered ring, and 6-10 membered ring and the like.
- leaving group refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (for example, an affinity substitution reaction).
- substituent groups include triflate; chlorine, bromine, iodine; sulfonate, such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonate, etc.; acyloxy, such as acetoxy, trifluoroacetoxy, etc.
- protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
- amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); arylmethyloxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethyls
- hydroxyl protecting group refers to a protecting group suitable for preventing side reactions of the hydroxyl group.
- Representative hydroxy protecting groups include but are not limited to: alkyl groups, such as methyl, ethyl, and tert-butyl; acyl groups, such as alkanoyl (such as acetyl); arylmethyl, such as benzyl (Bn), p-methyloxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS) and so on.
- alkyl groups such as methyl, ethyl, and tert-butyl
- acyl groups such as alkanoyl (such as acetyl)
- arylmethyl such as benzyl (Bn), p-methyloxybenzyl (PMB), 9-
- the compounds of the present disclosure can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by their combination with other chemical synthesis methods, and equivalents or alternatives thereof known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present disclosure.
- aq stands for water
- HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
- EDC stands for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
- m-CPBA stands for 3-chloroperoxybenzoic acid
- eq stands for equivalent
- CDI stands for carbonyl diimidazole
- DCM stands for dichloromethane
- PE stands for petroleum ether
- DIAD diisopropyl azodicarboxylate
- DMF stands for N,N-dimethylformamide
- DMSO stands for dimethyl sulfoxide
- EtOAc stands for ethyl acetate
- EtOH stands for ethanol
- MeOH stands for methanol
- CBz stands for benzyloxy
- THF tetrahydrofuran
- Boc 2 O stands for di-tert-butyl dicarbonate
- TFA trifluoroacetic acid
- DIPEA diisopropylethylamine
- SOCl 2 stands for thionyl chloride
- CS 2 carbon disulfide
- TsOH stands for p-toluenesulfonic acid
- NFSI stands for N-fluoro-N-(benzenesulfonyl)benzenesulfonamide
- NCS stands for 1-chloropyrrolidine-2,5-dione
- n-Bu 4 NF stands for tetrabutylammonium fluoride
- iPrOH stands for 2-propanol
- mp stands for melting point
- EDCI stands for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
- the compound of the present disclosure has a good inhibitory effect on the mutant IDH1R132H and IDH1R132C, and at the same time has no inhibitory effect on the wild-type IDH protein; at the cellular level, the compound of the present disclosure has a good 2-HG inhibitory effect on U87MG glioma cells with IDH1R132H mutation; the compound of the present disclosure has significant IDH1 mutant inhibitory effect and good selectivity, and at the same time has a better distribution ratio in brain tumors and parabrain tissues, which may reduce potential side effects on normal brain tissues
- Example 1B Under the protection of nitrogen gas, nickel chloride (1.99 g, 15.32 mmol) was added to a solution of Example 1A (1 g, 3.06 mmol) in methanol (20 mL), and after cooling to 0°C, sodium borohydride (695.57 mg, 18.39 mmol) was slowly added, and the mixed solution was stirred at 15°C for 1 hour. The reaction was quenched by adding 100 mL of saturated ammonium chloride solution and stirring for 15 minutes. The reaction solution was extracted with ethyl acetate (80 mL ⁇ 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 1B, which was used directly in the next step without purification.
- Example 1B 4-(trifluoromethoxy)phenyl isothiocyanate (888.84 mg, 4.06 mmol) was added to a solution of Example 1B (1.1 g, 3.69 mmol) in tetrahydrofuran (20 mL), stirred at 40°C for half an hour, then EDC ⁇ HCl (1.41 g, 7.37 mmol) was added and stirred at 70°C for 16 hours.
- the reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 1C.
- Lithium hydroxide (334.35 mg, 13.96 mmol) was added to a solution of Example 1C (1.35 g, 2.79 mmol) in tetrahydrofuran (10 mL) and water (10 mL), stirred at 15°C for 16 hours, and the reaction solution was adjusted to pH 6 with 1M hydrochloric acid.
- the reaction solution was extracted with ethyl acetate (30 mL ⁇ 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product.
- the crude product was diluted with 5 ml of ethyl acetate, and then 20 ml of petroleum ether was added to precipitate a white solid.
- Example 2B Under the protection of nitrogen gas, nickel chloride (1.99 g, 15.32 mmol) was added to a solution of Example 2A (1 g, 3.06 mmol) in methanol (20 mL), and after cooling to 0°C, sodium borohydride (695.57 mg, 18.39 mmol) was slowly added, and the mixed solution was stirred at 15°C for 1 hour. The reaction was quenched by adding 100 mL of saturated ammonium chloride solution and stirring for 15 minutes. The reaction solution was extracted with ethyl acetate (80 mL ⁇ 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 2B, which was used directly in the next step without purification.
- Example 2C 4-(trifluoromethoxy)phenyl isothiocyanate (767.64 mg, 3.50 mmol) was added to a solution of Example 2B (950.00 mg, 3.18 mmol) in tetrahydrofuran (2 mL), stirred at 40°C for half an hour, then EDCI (1.22 g, 6.37 mmol) was added and stirred at 70°C for 16 hours.
- the reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 2C.
- Lithium hydroxide (329.42 mg, 13.75 mmol) was added to a mixed solution of Example 2C (1.33g, 2.75mmol) in tetrahydrofuran (10 mL) and water (10 mL), stirred at 15°C for 16 hours, and the reaction solution was adjusted to pH 6 with 1M hydrochloric acid.
- the reaction solution was extracted with ethyl acetate (30 mL ⁇ 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product.
- the crude product was diluted with 5 ml of ethyl acetate, and then 20 ml of petroleum ether was added to precipitate a white solid.
- Example 2 The solid was filtered, concentrated under reduced pressure, and then diluted with 10 ml of methyl tert-butyl ether, stirred for ten minutes, filtered, and the solid was concentrated under reduced pressure to obtain Example 2.
- Example 3A The combined organic layer was washed with 200 mL (100 mL ⁇ 2) of saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography to obtain Example 3A.
- Example 3A To a solution of Example 3A (1.01 g, 2.80 mmol) in methanol (10 mL) and tetrahydrofuran (6 mL), nickel chloride (3.33 g, 14.00 mmol) was added and then a solution of sodium borohydride (1.38 g, 36.39 mmol) in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 1 hour. Water (80 mL) and ethyl acetate (30 mL) were added to the mixture and filtered through a pad of celite.
- Example 3B The filter cake was washed with ethyl acetate (40 mL ⁇ 3), and the filtrate was extracted with 150 mL of ethyl acetate. The combined organic phase was washed with saturated brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 3B, which was used directly in the next step without purification.
- Example 3B 1-isothiocyanato-4-(trifluoromethoxy)benzene (515.06 mg, 2.35 mmol, 381.52 ⁇ L) was added to a solution of Example 3B (711 mg, 2.14 mmol) in tetrahydrofuran (8 mL), and the mixture was stirred at 45°C for 1 hour, then EDCI (409.53 mg, 2.14 mmol) was added and the mixture was stirred at 70 °C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 50 mL of water and extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
- Lithium hydroxide (288.84 mg, 6.88 mmol) was added to a solution of Example 3C (713 mg, 1.38 mmol) in tetrahydrofuran (4 mL) and water (2 mL), and the mixture was stirred at 20°C for 16 hours.
- the combined organic layer was washed with 200 mL (100 mL ⁇ 2) of saturated aqueous salt solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue.
- Example 3D The residue was purified by high performance liquid chromatography (TFA conditions) to obtain Example 3D.
- Example 4A To a solution of Example 4A (1.01 g, 2.93 mmol) in methanol (6 mL) and tetrahydrofuran (6 mL), nickel chloride (3.49 g, 14.67 mmol) was added and then a solution of sodium borohydride (1.4g, 38.1mmol) in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 1 hour. The mixture was poured into water (80 mL) and ethyl acetate (30 mL) and filtered through a pad of celite.
- Example 4B The filter cake was washed with ethyl acetate (40 mL ⁇ 3), the mixture was extracted with 150 mL of ethyl acetate. The combined organic phase was washed with saturated brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 4B, which was used directly in the next step without purification.
- Example 4B 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (313.22 mg, 1.43 mmol) was added to a solution of Example 4B (411 mg, 1.30 mmol) in tetrahydrofuran (6 mL), and the mixture was stirred at 45°C for 1 hour, then EDCI (249.04 mg, 1.30 mmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 50 mL of water and extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
- Example 4C The combined organic layer was washed with 100 mL (50 mL ⁇ 2) of aqueous solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography to obtain Example 4C, which was used directly in the next step without purification.
- Lithium hydroxide (139.33 mg, 3.32 mmol) was added to a solution of Example 4C (333 mg, 664.05 ⁇ mol) in tetrahydrofuran (4 mL) and water (2 mL), and the mixture was stirred at 20°C for 16 hours.
- the combined organic layer was washed with 200mL (100mL ⁇ 2) of saline solution, and dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue.
- Example 4 The residue was purified by high performance liquid chromatography (TFA conditions) to obtain Example 4.
- Example 5A which was used directly in the next step without purification.
- Example 5A 400 mg, 1.18 mmol
- nickel dichloride hexahydrate (1.12 g, 4.70 mmol) was added and then a solution of sodium borohydride (88.92 mg, 2.35 mmol) in dimethylformamide (1 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 2 hours, then sodium borohydride (177.84 mg, 4.70 mmol) was added in batches at 0°C and stirred at 15°C 2 hours. The reaction mixture was diluted with water (20 mL) and then filtered.
- Example 5B which was used directly in the next step without purification.
- Example 5B 4-(trifluoromethoxy)phenylthio isocyanate (270.12 mg, 1.23 mmol) was added to a solution of Example 5B (350 mg, 1.12 mmol) in tetrahydrofuran (5 mL), and the mixture was stirred at 25°C for 1 hour. Then EDCI (429.54 mg, 2.24 mmol) was added to the mixture and reacted at 70°C for 2 hours. The reaction mixture was concentrated under reduced pressure to remove tetrahydrofuran. The residue was diluted with water (10 mL) and extracted with ethyl acetate (10 mL ⁇ 3).
- Example 5C which was used directly in the next step without further purification.
- Example 5C Lithium hydroxide monohydrate (126.52 mg, 3.02 mmol) was added to a solution of Example 5C (500 mg, 1.01 mmol) in water (5 mL), and the mixture was stirred at 20°C for 16 hours. The mixture was adjusted to pH 6-7 with HCl (1M aqueous solution), and extracted with ethyl acetate (10 mL ⁇ 4). The combined organic layer was washed with brine (20m ⁇ 1), dried with anhydrous sodium sulfate, and filtered and concentrated under reduced pressure to obtain the residue, which was separated and purified by high performance liquid chromatography (TFA conditions) to obtain Example 5.
- TFA conditions high performance liquid chromatography
- Example 6A which was used directly in the next step without purification.
- Example 6A To a solution of Example 6A (1.31 g, 3.72 mmol) in methanol (10 mL) was added nickel chloride (4.42 g, 18.59 mmol), and then a solution of sodium borohydride (1.97 g, 52.05 mmol) dissolved in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 16 hours. The mixture was poured into water (100mL), ethyl acetate (40mL) and filtered through a pad of celite.
- Example 6B which was used directly in the next step without purification.
- Example 6B To a solution of Example 6B (1.09 g, 2.99 mmol) in tetrahydrofuran (15 mL) was added isothiocyanoyl-4-(trifluoromethoxy)benzene (720.97 mg, 3.29 mmol), and the mixture was stirred at 50°C for 1 hour. Then EDCI (573.25 mg, 2.99 mmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL ⁇ 2) of ethyl acetate.
- Example 6 The residue was dissolved in EA (10 mL) and stirred at 25 °C for 30 min, then the mixture was filtered and washed with ethyl acetate (2 ⁇ 10 mL) to obtain Example 6.
- Example 7A was purified by column chromatography to obtain Example 7A as a yellow oil.
- nickel chloride (1.42 g, 10.95 mmol) was added to a solution of Example 7A (0.79 g, 2.19 mmol) in methanol (10 mL), and after cooling to 0°C, sodium borohydride (828.40 mg, 21.90 mmol) was slowly added, and the mixed solution was stirred at 15°C for 0.5 hour. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution and stirring for 15 minutes.
- Example 7B was used directly in the next step without further purification.
- Example 7B To a solution of Example 7B (0.615g, 1.85mmol) in tetrahydrofuran (10mL) was added 4-(trifluoromethoxy)phenyl isothiocyanate (486.02 mg, 2.22 mmol, 360.01 ⁇ L), the mixture was stirred at 40°C for 0.5 hour, then EDC ⁇ HCl (708.46 mg, 3.70 mmol) was added and stirred at 70°C for 5 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purification by column chromatography to obtain Example 7C as a yellow solid.
- Example 7C Lithium hydroxide (234.96 mg, 5.60 mmol) was added to a mixed solution of Example 7C (0.58g, 1.12mmol) in tetrahydrofuran (5 mL) and water (5 mL), and stirred at 20°C for 16 hours.
- the reaction solution was adjusted to pH 6 with 1M hydrochloric acid, then diluted with 30 mL of water, and extracted with ethyl acetate (30 mL ⁇ 3).
- the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product.
- the crude product was purified by high performance liquid chromatography to obtain Example 7.
- Example 8A 720 mg, 2.13 mmol
- MeOH 20 mL
- DMF 5 mL
- NiCl 2 ⁇ 6H 2 O 2.02g, 8.51mmol
- NaBH 4 563.54mg, 14.90mmol
- the mixture was stirred at 0°C for 1 hour.
- the reaction mixture was quenched by adding water (50 mL) and then diluted with ethyl acetate (50 mL).
- the mixture was filtered and extracted with ethyl acetate (30 mL ⁇ 3).
- the combined organic layer was washed with brine (100 mL ⁇ 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 8B as a brown oil.
- the residue was used directly in the next step without further purification.
- Example 8B To a solution of Example 8B (800 mg, 2.58 mmol) in THF (10 mL) was added 4-(trifluoromethoxy)phenyl isothiocyanate (677.91 mg, 3.09 mmol, 502.16 ⁇ L). The mixture was stirred at 30°C for 1 h. Then EDCI (988.19 mg, 5.15 mmol) was added and the mixture was stirred at 70°C for 2 hours. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL ⁇ 3). The combined organic layer was washed with brine (30 mL ⁇ 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue.
- Example 8C was purified by column chromatography to obtain Example 8C as a brown oil.
- Example 8C 450 mg, 908.19 ⁇ mol
- THF 2 mL
- H 2 O 2 mL
- LiOH.H 2 O 114.33 mg, 2.72 mmol
- the mixture was stirred at 20°C for 16 hours.
- the mixture was adjusted to pH 7 with aqueous HCl (1M), and then extracted with ethyl acetate (10 mL ⁇ 3).
- the combined organic layer was washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure, and purified by high performance liquid chromatography to obtain Example 8.
- Example 9A was purified by column chromatography to obtain Example 9A as a yellow solid.
- nickel chloride (1.10 g, 8.50 mmol) was added to a solution of Example 9A (0.66 g, 1.70 mmol) in methanol (10 mL), and after cooling to 0°C, sodium borohydride (642.86 mg, 16.99 mmol) were added slowly. The mixed solution was stirred at 20°C for 0.5 hour. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution and stirring for 15 minutes.
- Example 9B was used directly in the next step without purification.
- Example 9B To a solution of Example 9B (0.41g, 1.14mmol) in tetrahydrofuran (10 mL), 4-(trifluoromethoxy)phenyl isothiocyanate (278 mg, 1.27 mmol, 205.93 ⁇ L) was added and stirred at 40°C for 1 hour. Then EDC ⁇ HCl (436.11 mg, 2.27 mmol) was added and stirred at 70°C for 12 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 9C as a yellow solid.
- Example 9C To a solution of Example 9C (0.46g, 843.18 ⁇ mol) in tetrahydrofuran (5mL) and water (5mL), lithium hydroxide monohydrate (176.92mg, 4.22mmol) was added and stirred at 20°C for 12 hours.
- the reaction solution was adjusted to pH 6 with 1M hydrochloric acid, and extracted with ethyl acetate (20 mL ⁇ 3).
- the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product.
- Example 10A To a solution of Example 10A (1.19 g, 3.34 mmol) in methanol (10 mL), nickel chloride (3.97 g, 16.70 mmol) was added, and then a solution of sodium borohydride (1.39 g, 36.73 mmol) in dimethylformamide (5 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 16 hours. The mixture was poured into water (100 mL), and ethyl acetate (40 mL) and filtered through a pad of celite.
- Example 10B The filter cake was washed with ethyl acetate (60 mL ⁇ 3) and the filtrate was extracted with 150 mL of ethyl acetate. The combined organic phases was washed with saturated brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 10B.
- Example 10B To a solution of Example 10B (1.11g, 3.35mmol) in tetrahydrofuran (15 mL), 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (734.27 mg, 3.35 mmol, 543.90 ⁇ L) was added, and the mixture was stirred at 50°C for 1 hour, then EDCI (642.11 mg, 3.35 mmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL ⁇ 2) of ethyl acetate.
- Example 10C To a solution of Example 10C (1.32 g, 2.49 mmol) in tetrahydrofuran (6 mL) and water (3 mL), lithium hydroxide monohydrate (523.12 mg, 12.47 mmol) was added and the mixture was stirred at 25°C for 16 hours.
- the combined organic layer was washed with 200 mL (100 mL ⁇ 2) of saturated saline solution, and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- Example 10 The resulting residue was dissolved in a mixed solution of ethyl acetate (4 mL) and petroleum ether (8 mL) and stirred at 25°C for 60 minutes. The mixture was filtered and the filter cake was washed with a mixed solution of ethyl acetate (1 mL) and petroleum ether (2 mL), to obtain Example 10.
- Example 11A 420 mg, 1.14 mmol
- nickel chloride (1.35 g, 5.70 mmol) was added and then a solution of sodium borohydride (474.42 mg, 12.54 mmol) in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 2 hours.
- the mixture was poured into water (80 mL), ethyl acetate (20 mL) and filter through a pad of celite. The filter cake was washed with ethyl acetate (50 mL ⁇ 3), and the mixture was extracted with 100 mL of ethyl acetate.
- the combined organic phase was washed with saturated brine (80 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 11B, which was used directly in the next step without purification.
- Example 11B To a solution of Example 11B (270 mg, 793.05 ⁇ mol) in tetrahydrofuran (5 mL), 1-isothiocyanato-4-(trifluoromethoxy)benzene (173.82 mg, 793.05 ⁇ mol, 128.76 ⁇ L) was added and the mixture was stirred at 50°C for 1 hour, then EDCI (167.23 mg, 872.35 ⁇ mol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL of ethyl acetate (100 mL ⁇ 2).
- Example 12 was obtained as a yellow oil.
- Example 12A To Example 12A (388 mg, 1.10 mmol) and nickel chloride hexahydrate (1.31 g, 5.51 mmol), MeOH (6 mL) and THF (6 mL) were added, and sodium borohydride (416.54 mg, 11.01 mmol) was added in batches at 5°C, and stirred at 5°C for 0.5 hours.
- the reaction mixture was quenched by adding 100 mL of water, filtered, and the filtrate was extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
- the combined organic layer was washed with 50 mL (50 mL ⁇ 1) of brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 12B.
- Example 12B To a solution of Example 12B (280 mg, 863.09 ⁇ mol) in THF (15 mL), isothiocyanoyl-4-(trifluoromethoxy)benzene (227.01 mg, 1.04 mmol, 168.16 ⁇ L) was added. After the addition, the mixture was stirred at 40°C for 1 hour, and then EDCI (330.91 mg, 1.73 mmol) was added and stirred at 70°C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove THF, diluted with 80 mL of water and extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
- Example 12C was obtained as a colorless oil.
- 3,3-Dimethylinden-1-one (3 g, 18.73 mmol) was dissolved in toluene (40 mL), into which titanium tetraisopropoxide (10.64 g, 37.46 mmol, 11.05 mL) and 2-methylpropane-2-sulfinamide (2.72 g, 22.48 mmol) were added, stirred at 60°C for 24 hours, then 2-methylpropane-2-sulfinamide (2.72 g, 22.48 mmol) and titanium tetraisopropoxide (5.32 g, 18.73 mmol, 5.53mL) were further added and stirred at 110°C for 16 hours.
- reaction mixture was quenched by adding 200 mL of water, and then filtered.
- the filtrate was extracted with 160 mL (80 mL ⁇ 2) of ethyl acetate.
- the combined organic layer was washed with 80 mL (80 mL ⁇ 1) of brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure, and purified by column chromatography to obtain compound Example 13A as a brown oil.
- Example 13A (1.4 g, 5.32 mmol) was dissolved in THF (20 mL) and water (574.67 mg, 31.89 mmol, 574.67 ⁇ L), into which sodium borohydride (1.01 g, 26.58 mmol) was added, and the mixture was stirred at 25°C for 4 hours.
- the reaction mixture was quenched by adding 100 mL of water, and then extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
- the combined organic layer was washed with 50 mL of saturated saline solution, dried over sodium sulfate, filtered and concentrated under reduced pressure, and purified by column chromatography to obtain compound Example 13B as a white solid.
- Example 13B To a solution of Example 13B (810 mg, 3.05 mmol) in MeOH (8 mL), HCl/dioxane (4M, 3mL) was added and stirred at 20°C for 0.5 hours. The mixture was diluted with methyl tert-butyl ether (15 mL) and stirred at 25°C for 30 minutes, filtered, and dried in vacuum to obtain Example 13C as a white solid.
- Example 13D methyl (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoate (400 mg, 1.78 mmol) in THF (12mL), potassium carbonate (982.04mg, 7.11mmol) and Example 13C (491.69mg, 2.49mmol) were added and stirred at 65°C for 16 hours.
- the mixture was diluted with 100 mL of water and extracted with 120 mL (60 mL ⁇ 2) of ethyl acetate.
- the combined organic layer was washed with 50 mL (50 mL ⁇ 1) of brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, and purified by column chromatography to obtain Example 13D as a yellow oil.
- Example 13D (300 mg, 818.75 ⁇ mol) was dissolved in THF (5mL) and MeOH (5mL), into which Pd/C (50mg, 10%) was added, the atmosphere was replaced with hydrogen gas for 3 times, and the mixture was stirred at 25 °C under H 2 (15psi) for 16 hours. After filtration, the filtrate was concentrated under reduced pressure to obtain Example 13E as a brown oil.
- Example 13E (255 mg, 753.45 ⁇ mol) was dissolved in THF (8 mL), into which 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (198.17 mg, 904.14 ⁇ mol, 146.79 ⁇ L) was added and stirred at 40°C for 1 hour, then EDCI (288.87 mg, 1.51 mmol) was added and stirred at 70°C for 1 hour.
- the reaction mixture was concentrated under reduced pressure to remove THF, diluted with 80 mL of water and extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
- Example 13F as a white solid compound.
- 1 H NMR (400 MHz, CDCl 3 ) ⁇ 1.28 - 1.55 (m, 6 H) 2.14 - 2.72 (m, 4 H) 3.06 (br s, 2 H) 3.69 (s, 3 H) 5.50 (br s, 1 H) 6.06 (br s, 1 H) 6.92 - 7.60 (m, 11 H).
- a dry bottle was filled with 1-(trifluoromethyl)-1,2-benzoiodo-3-one (3.28 g, 10.37 mmol) and CuBr (123.96 mg, 864.15 ⁇ mol, 26.32 ⁇ L).
- the bottle was evacuated and backfilled with nitrogen gas for three times.
- azido(trimethyl)silane (2.49 g, 21.60 mmol, 2.84 mL) and styrene (900 mg, 8.64 mmol) dissolved in ACN (40 mL) were added to the above bottle.
- the reaction mixture was stirred at 40°C for 1.5 hours.
- the reaction mixture was diluted with water (40 mL) and extracted with DCM (20 mL ⁇ 3).
- Example 14A as a colorless oily compound.
- Example 14A To a solution of Example 14A (1.1g, 5.11mmol) in MeOH (15mL), CuSO 4 (81.59 mg, 511.21 ⁇ mol, 78.46 ⁇ L) and NaBH 4 (290.11 mg, 7.67 mmol) were added. The mixture was stirred at 0°C for 1 h and then at 20°C for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL ⁇ 3). The combined organic layer was washed with brine (20 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 14B as a brown oil, which was used in the next step without further purification.
- Example 14C To a solution of Example 14C (1 g, 2.54 mmol) in MeOH (20 mL), NiCl 2 ⁇ 6H 2 O (2.41 g, 10.14 mmol) was added, and then NaBH 4 (959.38 mg, 25.36 mmol) was added in portions at 0°C, and the mixture was kept at 0°C for 1 hour.
- the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL ⁇ 3). The combined organic layer was washed with brine (50 mL ⁇ 1), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain Example 14D as a brown oily residue, which was used directly in the next step without further purification.
- Example 14D To Example 14D (770 mg, 2.10 mmol) in THF (20 mL), 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (552.78 mg, 2.52 mmol, 409.47 ⁇ L) was added. The mixture was stirred at 40°C for 1 h. Then EDCI (805.79 mg, 4.20 mmol) was added and the mixture was stirred at 70°C for 2 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (30 mL ⁇ 3).
- Example 14E To a solution of Example 14E (220 mg, 398.93 ⁇ mol) in MeOH (3 mL) and H 2 O (3 mL), LiOH.H 2 O (50.22 mg, 1.20 mmol) was added. The mixture was stirred at 30°C for 16 h. The mixture was stirred at 30°C for another 3 hours. The mixture was adjusted to pH 5-6 with HCl (1M) solution to precipitate a solid, which was filtered and dried to obtain Example 14.
- Example 14F To a solution of Example 14F (300 mg, 543.99 ⁇ mol) in MeOH (4 mL) and H 2 O (4 mL), LiOH ⁇ H 2 O (68.48 mg, 1.63 mmol) was added. The mixture was stirred at 30°C for 16 hours. The mixture was adjusted to pH 5-6 with HCl (1M) solution to precipitate a solid, which was filtered and dried to obtain Example 15.
- the IDH1 mutant catalyzes the NADPH-dependent reduction of ⁇ -KG (a-ketoglutarate) to 2-HG (2-hydroxyglutarate), and the consumed NADPH can be read by fluorescence.
- Basic reaction buffer 50 mM KH 2 PO 4 , pH 7.5, 10 mM MgCl 2 , 10% glycerol, 150 mM NaCl, 0.05% BSA (bovine serum albumin), 2mM b-ME (2-mercaptoethanol), 0.003% Brij35 (polyethylene glycol lauryl ether)
- IDHlwt wild type: 65 ⁇ M isocitrate + 50 ⁇ M NADP
- IDH1(R132H) 1500 ⁇ M ⁇ -KG + 15 ⁇ M NADPH
- IDH1(R132C) 500 ⁇ M ⁇ -KG + 15 ⁇ M NADPH
- the compounds of the present disclosure have a good inhibitory effect on the mutant IDH1R132H and IDH1R132C, and at the same time have no inhibitory effect on the wild-type IDH protein.
- IDH1 catalyzes the reduction of isocitrate to ⁇ -ketoglutarate (a-KG) in organisms, and the IDH1 mutant further catalyzes the reduction of ⁇ -KG to 2-hydroxyglutarate (2HG).
- the U87MG-IDH1-R132H cell strain is a stable transfected cell strain that can stably express IDH1-R132H mutant, obtained via screening by transfecting U87MG cells with IDH1-R132H, and the HT1080 cell strain contains an endogenous IDH1-R132C mutant.
- the compounds of the present disclosure have a good 2-HG inhibitory effect on U87MG brain glioma cells with IDH1R132H mutation.
- Animals in group 1 were given a single injection of the drug at a dose of 1 mg/kg and a concentration of 0.5 mg/mL via tail vein, and animals in group 2 were given a compound at a dose of 20 mg/kg and a concentration of 2 mg/mL via gavage.
- Plasma samples were cross-collected from the animals at 0.0833 (tail vein injection group only), 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after administration.
- Example 6 of the present disclosure has good pharmacokinetic properties in mice.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the priority of
CN201810672394.3 filed on June 26, 2018 - The present disclosure relates to a series of benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof.
- Isocitrate dehydrogenase is an important enzyme in the citric acid cycle, and catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate (i.e. 2-α-ketoglutarate, α-KG). The protein encoded by the IDH 1 gene is NADP(+)-dependent isocitrate dehydrogenase comprising a PTS-1 peroxidase targeting signal sequence found in the cytoplasm and peroxisomes. The presence of this enzyme in peroxisomes suggests a role for internal NADPH regeneration.
-
- IDH 1/2 mutant protein (IDH 1/2 m) has been found in a variety of tumors, including glioma, acute myeloid leukemia (AML), chondrosarcoma, intrahepatic cholangioma, melanoma, prostate cancer, angioimmunoblastic T cell lymphoma. In gliomas, more than 70% of non-primary glioblastomas have IDH1 mutations, and 92.7% of IDH1 mutant tumors have arginine replaced by histidine (i.e. IDH1 R132H) (Hartmann C, Acta Neuropathol. 2009 Oct;1 18(4):469-74).
- The IDH mutant protein has a new function, that is, it catalyzes the reduction of α-KG to produce a carcinogenic metabolite 2-hydroxyglutarate (2-HG). The production of 2-HG is believed to contribute to the formation and development of cancer (Dang L , Nature, 2009 Dec 10;462(7274):739-44). Normal cells produce very low levels of 2-HG, but cells with IDH mutations are able to produce high levels of 2-HG. High levels of 2-HG can also be found in tumors with IDH mutations.
- Therefore, the inhibition of mutant IDH and the new activity thereof is a potential method for cancer treatment. Therefore, there is a need to obtain inhibitors of IDH mutants to inhibit the production of 2-HG.
-
-
- R1 is selected from C1-6 alkyl, C3-6 cycloalkyl and phenyl, the C1-6 alkyl, C3-6 cycloalkyl and phenyl being optionally substituted with 1, 2 or 3 Ra;
- R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, C1-6 alkyl and C1-6 alkoxy, the C1-6 alkyl and C1-6 alkoxy being optionally substituted with 1, 2 or 3 Rb;
- alternatively, R1 and R2 are joined together to form a C4-6 cycloalkenyl optionally substituted with 1, 2 or 3 Rc;
- L is selected from -CH2CH2- and -C3-6 cycloalkyl-CH2-;
- n is selected from 1, 2 and 3; and
- Ra, Rb, and Rc are each independently selected from F, Cl, Br, I, OH, NH2, CN, COOH, and Me;
- or an isomer thereof, or a pharmaceutically acceptable salt thereof.
- In some embodiments of the present disclosure, the above-mentioned R1 is selected from C1-3 alkyl, cyclopropanyl and phenyl, the C1-3 alkyl, cyclopropanyl and phenyl being optionally substituted with 1, 2 or 3 Ra, and other variables are as defined in the present disclosure.
-
- In some embodiments of the present disclosure, the above-mentioned R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, C1-3 alkyl and C1-3 alkoxy, the C1-3 alkyl and C1-3 alkoxy being optionally substituted with 1, 2 or 3 Rb, and other variables are as defined in the present disclosure.
- In some embodiments of the present disclosure, the above-mentioned R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, CH3 and CH3O, the CH3 and CH3O being optionally substituted with 1, 2 or 3 Rb, and other variables are as defined in the present disclosure.
- In some embodiments of the present disclosure, the above-mentioned R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, CH3, CH2F, CHF2, CF3 and OCH3, and other variables are as defined in the present disclosure.
-
-
-
-
-
- There are also some embodiments of the present disclosure obtained from any combination of the above variables.
-
- E is selected from -CH2-, -CH2CH2-, -C(CH3)2- and -C(CH3)2CH2-;
- L is selected from -CH2CH2- and
- R1, R2 and R3 are as defined in the present disclosure.
-
-
-
- The present disclosure also provides use of the above-mentioned compound, or an isomer thereof, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease related to IDH1.
- Unless otherwise stated, the following terms and phrases used herein are intended to have the following meanings. A specific term or phrase for which no special definition is provided should not be considered uncertain or unclear, but should be understood in its ordinary meaning. When a trade name appears herein, it is meant to refer to the corresponding commodity or the active ingredient thereof.
- The term "pharmaceutically acceptable" used herein refers to those compounds, materials, compositions and/or dosage forms that within the scope of reliable medical judgment are suitable for contacting with human and animal tissues, without excessive toxicity, irritation, allergic reactions or other problems or complications, and that are commensurate with a reasonable benefit/risk ratio.
- The term "pharmaceutically acceptable salt" refers to a salt of the compound of the present disclosure, which is prepared from a compound with specific substituents discovered in the present disclosure and a relatively non-toxic acid or base. When the compound of the present disclosure contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salt or similar salts. When the compound of the present disclosure contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloride, hydrobromide, nitrate, carbonate, bicarbonate, phosphate, monohydrogen phosphate, dihydrogen phosphate, sulfate, hydrogen sulfate, hydroiodide, phosphite, etc.; as well as organic acid salts, wherein the organic acid includes, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, octanedioic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluene sulfonic acid, citric acid, tartaric acid and methanesulfonic acid, etc.; and also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present disclosure contain both basic and acidic functional groups, and thus can be converted into any base or acid addition salt.
- The pharmaceutically acceptable salt of the present disclosure can be synthesized from the parent compound containing an acidic or basic functional group by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with stoichiometric amounts of appropriate bases or acids in water or organic solvents or a mixture of both.
- The compounds of the present disclosure may exist in specific geometric or isomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and the racemic mixture and other mixtures thereof, such as enantiomers or diastereomeric enriched mixtures, which are all within the scope of the present disclosure. Additional asymmetric carbon atoms may be present in a substituent, such as alkyl. All these isomers and their mixtures are included in the scope of the present disclosure.
- Unless otherwise specified, the term "enantiomer" or "optical isomer" refers to isomers that are mirror images of each other.
- Unless otherwise specified, the term "cis-trans isomer" or "geometric isomer" is caused by the inability to rotate freely because of double bonds or single bonds of ring-forming carbon atoms.
- Unless otherwise specified, the term "diastereomer" refers to stereoisomers which have two or more chiral centers and the molecules are non-mirror-image relationship.
- Unless otherwise specified, "(D)" or "(+)" means dextrorotation, "(L)" or "(-)" means levorotatory, and "(DL)" or "(±)" means racemic.
- Unless otherwise specified, the wedge-shaped solid line () and the wedge-shaped dashed line () are used to indicate the absolute configuration of a stereocenter, the straight solid line () and the straight dashed line () are used to indicate the relative configuration of a stereocenter, the wavy line () is used to indicate a wedge-shaped solid line () or a wedge-shaped dashed line (), and the wavy line () is used to indicate a straight solid line () and a straight dashed line ().
- Unless otherwise specified, for a compound in which there is a double bond, such as a carbon-carbon double bond, a carbon-nitrogen double bond, and a nitrogen-nitrogen double bond, and each atom on the double bond is connected to two different substituents (in a double bond containing a nitrogen atom, a lone pair of electrons on the nitrogen atom is regarded as a substituent connected thereto), if the atom on the double bond in the compound is connected to the substituent of the compound with a wavy line (), it means the (Z) isomer, (E) isomer or a mixture of two isomers of the compound. For example, the following formula (A) means that the compound exists as a single isomer of formula (A-1) or formula (A-2) or as a mixture of the two isomers of formula (A-1) and formula (A-2). The following formula (B) means that the compound exists as a single isomer of formula (B-1) or formula (B-2) or as a mixture of the two isomers of formula (B-1) and formula (B-2). The following formula (C) represents that the compound exists as a single isomer of formula (C-1) or formula (C-2) or as a mixture of the two isomers of formula (C-1) and formula (C-2).
- The compounds of the present disclosure may exist in specific forms. Unless otherwise specified, the term "tautomer" or "tautomeric form" means that at room temperature, the isomers with different functional groups are in dynamic equilibrium and can be transformed into each other quickly. If tautomers are possible (such as in a solution), the chemical equilibrium of the tautomers can be reached. For example, proton tautomer, also referred to as prototropic tautomer, includes interconversion through proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomer includes some recombination of bonding electrons for mutual transformation. A specific example of keto-enol tautomerization is the tautomerism between two tautomers pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
- Unless otherwise specified, the terms "enriched in one isomer", "isomer enrichment", "enriched in one enantiomer" or "enantiomeric enrichment" means that the content of one isomer or enantiomer is less than 100%, and the content of the isomer or enantiomer is 60% or greater, or 70% or greater, or 80% or greater, or 90 % or greater, or 95% or greater, or 96% or greater, or 97% or greater, or 98% or greater, or 99% or greater, or 99.5% or greater, or 99.6% or greater, or 99.7% or greater, or 99.8% or greater, or 99.9% or greater.
- Unless otherwise stated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80% .
- The optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. In order to obtain an enantiomer of a compound of the present disclosure, it can be prepared by asymmetric synthesis or derivatization with chiral auxiliary agents, in which the resulting mixture of diastereomers is separated, and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), it can form diastereomeric salts with appropriate optically active acids or bases, and then diastereomers can be resolved by conventional methods known in the art to recover the pure enantiomers. In addition, the separation of enantiomers and diastereomers is usually accomplished through the use of chromatography, which employs a chiral stationary phase and is optionally combined with chemical derivatization (for example, carbamate is generated from an amine). The compounds of the present disclosure may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound. For example, compounds can be labeled with radioisotopes, such as tritium (3H), iodine-125 (125I) or C-14 (14C). For another example, deuterated drugs can be formed by replacing hydrogen with deuterium. The bond between deuterium and carbon is stronger than that of ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have reduced toxic side effects and increased drug stability, enhanced efficacy, extend biological half-life and other advantages. All changes in the isotopic composition of the compounds of the present disclosure, whether radioactive or not, are included in the scope of the present disclosure.
- "Optional" or "optionally" means that the event or condition described later may but not necessarily occur, and the description includes both the situation where the event or condition occurs and the situation where the event or condition does not occur.
- The term "substituted" means that any one or more hydrogen atoms on a specific atom are replaced by substituents, including deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e. =O), it means that two hydrogen atoms are replaced. Oxygen substitution does not occur on aromatic groups. The term "optionally substituted" means that the group may be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrary on the basis that they can be chemically realized.
- When any variable (such as R) occurs more than once in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group can optionally be substituted with up to two Rs, and in each case R is selected independently. In addition, combinations of substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
- When the number of a linking group is 0, such as -(CRR)0-, it means that the linking group is a single bond.
- When one of the variables is selected from a single bond, it means that the two groups connected are directly connected. For example, when L in A-L-Z represents a single bond, it means that the structure is actually A-Z.
- When a substituent is vacant, it means that the substituent is absent. For example, when X in A-X is vacant, it means that the structure is actually A. When it is not specified through which atom the listed substituent is connected to the substituted group, such substituents can be bonded at any atom. For example, the pyridyl group as a substituent can be connected to the substituted group through any carbon atom on the pyridine ring. When it is not specified the connection direction of the listed linking groups, the connection direction is arbitrary. For example, if the linking group L in
- Unless otherwise specified, the term "C1-6 alkyl" is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 6 carbon atoms. The C1-6 alkyl group includes C1-5, C1-4, C1-3, C1-2, C2-6, C2-4, C6 and C5 alkyl groups, etc.; and can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methyne). Examples of C1-6 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, s-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl, etc.
- Unless otherwise specified, the term "C1-3 alkyl" is used to denote a linear or branched saturated hydrocarbon group composed of 1 to 3 carbon atoms. The C1-3 alkyl group includes C1-2 and C2-3 alkyl groups, etc.; and can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine). Examples of C1-3 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- Unless otherwise specified, the term "C1-6 alkoxy" refers to an alkyl group containing 1 to 6 carbon atoms that is attached to the rest of the molecule through an oxygen atom. The C1-6 alkoxy group includes C1-4, C1-3, C1-2, C2-6, C2-4, C6, C5, C4, C3 alkoxy, etc. Examples of C1-6 alkoxy include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexoxy and the like.
- Unless otherwise specified, the term "C1-3 alkoxy" refers to an alkyl group containing 1 to 3 carbon atoms that are attached to the rest of the molecule through an oxygen atom. The C1-3 alkoxy group includes C1-2, C2-3, C3 and C2 alkoxy groups, etc. Examples of C1-3 alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy) and the like.
- Unless otherwise specified, "C3-6 cycloalkyl" means a saturated cyclic hydrocarbon group composed of 3 to 6 carbon atoms, which is a monocyclic and bicyclic ring system. The C3-6 cycloalkyl includes C3-5, C4-5 and C5-6 cycloalkyl, etc.; and can be monovalent, divalent or multivalent. Examples of C3-6 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- Unless otherwise specified, "C4-6 cycloalkenyl" means a partially unsaturated cyclic hydrocarbon group composed of 4 to 6 carbon atoms containing at least one carbon-carbon double bond, which is monocyclic and bicyclic systems, wherein the bicyclic system includes spiro ring, fused ring and bridged ring, in which each ring is non-aromatic. The C4-6 cycloalkenyl group includes a C4-5 or C5-6 cycloalkenyl group, etc.; and may be monovalent, divalent or multivalent. Examples of C4-6 cycloalkenyl include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
- Unless otherwise specified, the terms "C6-12 aromatic ring" and "C6-12 aryl" can be used interchangeably herein. The term "C6-12 aromatic ring" or "C6-12 aryl" means a cyclic hydrocarbon group composed of 6 to 12 carbon atoms with a conjugated π-electron system, which can be a single ring, a fused bicyclic ring or condensed tricyclic ring system in which each ring is aromatic. It can be monovalent, divalent or multivalent. C6-12 aryl groups include C6-10, C6-9, C6-8, C12, C10, and C6 aryl groups. Examples of C6-12 aryl groups include, but are not limited to, phenyl, naphthyl (including 1-naphthyl, 2-naphthyl, etc.).
- Unless otherwise specified, Cn-n+m or Cn-Cn+m includes any specific case of n to n+m carbons, for example, C1-12 includes C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, and C12, including any range from n to n+m, for example, C1-12 includes C1-3, C1-6, C1-9, C3-6, C3-9, C3-12, C6-9, C6-12, and C9-12, etc. Similarly, n-membered to n+m-membered means that the number of atoms in the ring is from n to n+m, for example, a 3-12-membered ring includes a 3-membered ring , 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring, 9-membered ring, 10-membered ring, 11-membered ring, and 12-membered ring, including any range from n to n+m, for example, 3-12 membered ring includes 3-6 membered ring, 3-9 membered ring, 5-6 membered ring, 5-7 membered ring, 6-7 membered ring, 6-8 membered ring, and 6-10 membered ring and the like.
- The term "leaving group" refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (for example, an affinity substitution reaction). For example, representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate, such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonate, etc.; acyloxy, such as acetoxy, trifluoroacetoxy, etc.
- The term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "thiol protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); arylmethyloxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS) and so on. The term "hydroxyl protecting group" refers to a protecting group suitable for preventing side reactions of the hydroxyl group. Representative hydroxy protecting groups include but are not limited to: alkyl groups, such as methyl, ethyl, and tert-butyl; acyl groups, such as alkanoyl (such as acetyl); arylmethyl, such as benzyl (Bn), p-methyloxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS) and so on.
- The compounds of the present disclosure can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by their combination with other chemical synthesis methods, and equivalents or alternatives thereof known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present disclosure.
- The solvent used in the present disclosure is commercially available. The present disclosure uses the following abbreviations: aq stands for water; HATU stands for O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; EDC stands for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; m-CPBA stands for 3-chloroperoxybenzoic acid; eq stands for equivalent; CDI stands for carbonyl diimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DIAD stands for diisopropyl azodicarboxylate; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOAc stands for ethyl acetate; EtOH stands for ethanol; MeOH stands for methanol; CBz stands for benzyloxycarbonyl, which is an amine protecting group; BOC stands for tert-butoxycarbonyl which is an amine protecting group; HOAc stands for acetic acid; NaCNBH3 stands for sodium cyanoborohydride; r.t. stands for room temperature; O/N stands for overnight; THF stands for tetrahydrofuran; Boc2O stands for di-tert-butyl dicarbonate; TFA stands for trifluoroacetic acid; DIPEA stands for diisopropylethylamine; SOCl2 stands for thionyl chloride; CS2 stands for carbon disulfide; TsOH stands for p-toluenesulfonic acid; NFSI stands for N-fluoro-N-(benzenesulfonyl)benzenesulfonamide; NCS stands for 1-chloropyrrolidine-2,5-dione; n-Bu4NF stands for tetrabutylammonium fluoride; iPrOH stands for 2-propanol; mp stands for melting point; EDCI stands for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
- Compounds are named manually or by ChemDraw® software, and commercially available compounds are indicated by supplier catalog names.
- Technical effect: At the enzymatic level, the compound of the present disclosure has a good inhibitory effect on the mutant IDH1R132H and IDH1R132C, and at the same time has no inhibitory effect on the wild-type IDH protein; at the cellular level, the compound of the present disclosure has a good 2-HG inhibitory effect on U87MG glioma cells with IDH1R132H mutation; the compound of the present disclosure has significant IDH1 mutant inhibitory effect and good selectivity, and at the same time has a better distribution ratio in brain tumors and parabrain tissues, which may reduce potential side effects on normal brain tissues
- The following examples are intended to describe the present disclosure in detail, but are not meant to limit the present disclosure in any way. The present disclosure has been described in detail herein, and its specific embodiments are also disclosed. It will be obvious to those skilled in the art that various changes and improvements can be made to the specific embodiments of the present disclosure without departing from the spirit and scope of the present disclosure.
-
-
-
- Potassium carbonate (2.46 g, 17.76 mmol) was added to a solution of methyl (E)-3-(4-Fluoro-3-nitrophenyl)acrylate (2 g, 8.88 mmol) and (R)-1-phenylethylamine (1.18 g, 9.77 mmol, 1.26 mL) in tetrahydrofuran (20mL), and the mixed solution was stirred at 50°C for 16 hours. The reaction solution was diluted with 50 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. At 15°C, the crude product was stirred in petroleum ether: ethyl acetate = 10:1 (11 mL) for 30 minutes, filtered, and the solid was concentrated under reduced pressure to obtain Example 1A. 1H NMR (400MHz, CDCl3) δ= 8.65 (d, J=5.4 Hz, 1H), 8.35 (d, J=2.1 Hz, 1H), 7.60 - 7.44 (m, 2H), 7.42 - 7.29 (m, 5H), 6.70 (d, J=8.9 Hz, 1H), 6.27 (d, J=15.9 Hz, 1H), 4.76 (q, J=6.5 Hz, 1H), 3.80 (s, 3H), 1.70 (d, J=6.7 Hz, 3H).
-
- Under the protection of nitrogen gas, nickel chloride (1.99 g, 15.32 mmol) was added to a solution of Example 1A (1 g, 3.06 mmol) in methanol (20 mL), and after cooling to 0°C, sodium borohydride (695.57 mg, 18.39 mmol) was slowly added, and the mixed solution was stirred at 15°C for 1 hour. The reaction was quenched by adding 100 mL of saturated ammonium chloride solution and stirring for 15 minutes. The reaction solution was extracted with ethyl acetate (80 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 1B, which was used directly in the next step without purification.
-
- 4-(trifluoromethoxy)phenyl isothiocyanate (888.84 mg, 4.06 mmol) was added to a solution of Example 1B (1.1 g, 3.69 mmol) in tetrahydrofuran (20 mL), stirred at 40°C for half an hour, then EDC·HCl (1.41 g, 7.37 mmol) was added and stirred at 70°C for 16 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 1C. 1H NMR (400MHz, CDCl3) δ = 7.43 - 7.29 (m, 6H), 7.21 - 7.17 (m, 2H), 7.09 - 6.98 (m, 3H), 6.91 (br d, J=7.9 Hz, 1H), 5.80 (br s, 1H), 5.67 (q, J=7.1 Hz, 1H), 3.70 - 3.48 (m, 3H), 2.98 (t, J=7.9 Hz, 2H), 2.61 (t, J=7.9 Hz, 2H), 1.82 (d, J=7.1 Hz, 3H).
-
- Lithium hydroxide (334.35 mg, 13.96 mmol) was added to a solution of Example 1C (1.35 g, 2.79 mmol) in tetrahydrofuran (10 mL) and water (10 mL), stirred at 15°C for 16 hours, and the reaction solution was adjusted to pH 6 with 1M hydrochloric acid. The reaction solution was extracted with ethyl acetate (30 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was diluted with 5 ml of ethyl acetate, and then 20 ml of petroleum ether was added to precipitate a white solid. The solid was filtered, concentrated under reduced pressure, and then diluted with 10 ml of methyl tert-butyl ether, stirred for ten minutes, filtered, and the solid was concentrated under reduced pressure to obtain Example 1. 1H NMR (400MHz, METHANOL-d4) δ = 7.57 (br d, J=8.9 Hz, 2H), 7.43 - 7.21 (m, 8H), 6.90 - 6.63 (m, 2H), 5.97 (br d, J=6.8 Hz, 1H), 3.02 - 2.83 (m, 2H), 2.59 (br t, J=7.0 Hz, 2H), 2.03 - 1.92(m,3H)
-
-
- Potassium carbonate (2.46g, 17.76mmol) was added to a solution of methyl (E)-3-(4-fluoro-3-nitrophenyl)acrylate (2 g, 8.88 mmol) and (S)-1-phenylethylamine (1.08 g, 8.88 mmol) in tetrahydrofuran (20 mL), and the mixed solution was stirred at 50°C for 16 hours. The reaction solution was diluted with 50 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. At 15°C, the crude product was stirred in petroleum ether: ethyl acetate = 10:1 (11 mL) for 30 minutes, filtered, and the solid was concentrated under reduced pressure to obtain Example 2A. 1H NMR (400MHz, CDCl3) δ =8.65 (br d, J=5.5 Hz, 1H), 8.35 (d, J=2.1 Hz, 1H), 7.56 (d, J=15.9 Hz, 1H), 7.47 (dd, J=2.0, 8.9 Hz, 1H), 7.41 - 7.29 (m, 5H), 6.70 (d, J=9.0 Hz, 1H), 6.27 (d, J=15.9 Hz, 1H), 4.76 (q, J=6.5 Hz, 1H), 3.80 (s, 3H), 1.70 (d, J=6.7 Hz, 3H).
-
- Under the protection of nitrogen gas, nickel chloride (1.99 g, 15.32 mmol) was added to a solution of Example 2A (1 g, 3.06 mmol) in methanol (20 mL), and after cooling to 0°C, sodium borohydride (695.57 mg, 18.39 mmol) was slowly added, and the mixed solution was stirred at 15°C for 1 hour. The reaction was quenched by adding 100 mL of saturated ammonium chloride solution and stirring for 15 minutes. The reaction solution was extracted with ethyl acetate (80 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 2B, which was used directly in the next step without purification.
-
- 4-(trifluoromethoxy)phenyl isothiocyanate (767.64 mg, 3.50 mmol) was added to a solution of Example 2B (950.00 mg, 3.18 mmol) in tetrahydrofuran (2 mL), stirred at 40°C for half an hour, then EDCI (1.22 g, 6.37 mmol) was added and stirred at 70°C for 16 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 2C. 1H NMR (400MHz, CDCl3) δ = 7.43 - 7.27 (m, 6H), 7.23 - 7.17 (m, 2H), 7.07 - 6.97 (m, 3H), 6.95 - 6.86 (m, 1H), 5.82 (br s, 1H), 5.67 (q, J=7.0 Hz, 1H), 3.61 (s, 3H), 2.97 (t, J=7.9 Hz, 2H), 2.61 (t, J=7.9 Hz, 2H), 1.82 (d, J=7.1 Hz, 3H).
-
- Lithium hydroxide (329.42 mg, 13.75 mmol) was added to a mixed solution of Example 2C (1.33g, 2.75mmol) in tetrahydrofuran (10 mL) and water (10 mL), stirred at 15°C for 16 hours, and the reaction solution was adjusted to pH 6 with 1M hydrochloric acid. The reaction solution was extracted with ethyl acetate (30 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was diluted with 5 ml of ethyl acetate, and then 20 ml of petroleum ether was added to precipitate a white solid. The solid was filtered, concentrated under reduced pressure, and then diluted with 10 ml of methyl tert-butyl ether, stirred for ten minutes, filtered, and the solid was concentrated under reduced pressure to obtain Example 2. 1H NMR (400MHz, METHANOL-d4) δ =7.56 (br d, J=7.2 Hz, 2H), 7.42 - 7.22 (m, 8H), 6.86 - 6.71 (m, 2H), 6.03 - 5.88 (m, 1H), 2.98 - 2.87 (m, 2H), 2.63 - 2.53 (m, 2H), 2.05 - 1.92 (m, 3H).
-
-
- Potassium carbonate (982.04 mg, 7.11 mmol) and (1R)-1-(4-chlorophenyl)ethylamine (552.91 mg, 3.55 mmol) were added to a solution of (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoic acid methyl ester (800 mg, 3.55 mmol) in tetrahydrofuran (15mL), and the mixture was stirred at 45°C for 20 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 300 mL (100 mL×3) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography to obtain Example 3A. 1H NMR (400MHz, CDCl3) δ = 8.58 (br d, J=5.4 Hz, 1H), 8.34 (d, J=2.1 Hz, 1H), 7.55 (d, J=16.0 Hz, 1H), 7.47 (dd, J=2.1, 9.0 Hz, 1H), 7.36 - 7.32 (m, 2H), 7.29 - 7.27 (m, 2H), 6.62 (d, J=9.0 Hz, 1H), 6.27 (d, J=16.0 Hz, 1H), 4.71 (quin, J=6.4 Hz, 1H), 3.79 (s, 3H), 1.66 (d, J=6.7 Hz, 3H).
-
- To a solution of Example 3A (1.01 g, 2.80 mmol) in methanol (10 mL) and tetrahydrofuran (6 mL), nickel chloride (3.33 g, 14.00 mmol) was added and then a solution of sodium borohydride (1.38 g, 36.39 mmol) in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 1 hour. Water (80 mL) and ethyl acetate (30 mL) were added to the mixture and filtered through a pad of celite. The filter cake was washed with ethyl acetate (40 mL×3), and the filtrate was extracted with 150 mL of ethyl acetate. The combined organic phase was washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 3B, which was used directly in the next step without purification.
-
- 1-isothiocyanato-4-(trifluoromethoxy)benzene (515.06 mg, 2.35 mmol, 381.52 µL) was added to a solution of Example 3B (711 mg, 2.14 mmol) in tetrahydrofuran (8 mL), and the mixture was stirred at 45°C for 1 hour, then EDCI (409.53 mg, 2.14 mmol) was added and the mixture was stirred at 70 °C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 50 mL of water and extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 100 mL (50 mL×2) of saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 10:1) to obtain Example 3C, which was used directly in the next step without purification.
-
- Lithium hydroxide (288.84 mg, 6.88 mmol) was added to a solution of Example 3C (713 mg, 1.38 mmol) in tetrahydrofuran (4 mL) and water (2 mL), and the mixture was stirred at 20°C for 16 hours. The mixture was acidified to pH=6 with dilute hydrochloric acid (1N), and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saturated aqueous salt solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by high performance liquid chromatography (TFA conditions) to obtain Example 3D. 1H NMR (400MHz, DMSO-d6) δ = 7.78 (br s, 2H), 7.47 (s, 6H), 7.26 (s, 1H), 6.98 - 6.76 (m, 2H), 6.14 - 6.03 (m, 1H), 3.42 (br s, 2H), 2.85 (br t, J=7.3 Hz, 2H), 1.96 (br d, J=6.7 Hz, 3H).
-
-
- Potassium carbonate (982.04 mg, 7.11 mmol) and (1R)-1-(4-fluorophenyl)ethylamine (494.45 mg, 3.55 mmol) were added to a solution of (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoic acid methyl ester (800 mg, 3.55 mmol) in tetrahydrofuran (15mL), and the mixture was stirred at 45°C for 20 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 300 mL (100 mL×3) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 5:1) to obtain Example 4A. 1H NMR (400MHz, CDCl3) δ = 8.59 (br d, J=5.1 Hz, 1H), 8.34 (d, J=2.2 Hz, 1H), 7.55 (d, J=15.9 Hz, 1H), 7.48 (dd, J=2.1, 8.9 Hz, 1H), 7.34 - 7.28 (m, 2H), 7.09 - 7.01 (m, 2H), 6.65 (d, J=8.9 Hz, 1H), 6.27 (d, J=16.0 Hz, 1H), 4.73 (quin, J=6.5 Hz, 1H), 3.79 (s, 3H), 1.66 (d, J=6.7 Hz, 3H).
-
- To a solution of Example 4A (1.01 g, 2.93 mmol) in methanol (6 mL) and tetrahydrofuran (6 mL), nickel chloride (3.49 g, 14.67 mmol) was added and then a solution of sodium borohydride (1.4g, 38.1mmol) in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 1 hour. The mixture was poured into water (80 mL) and ethyl acetate (30 mL) and filtered through a pad of celite. The filter cake was washed with ethyl acetate (40 mL×3), the mixture was extracted with 150 mL of ethyl acetate. The combined organic phase was washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 4B, which was used directly in the next step without purification.
-
- 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (313.22 mg, 1.43 mmol) was added to a solution of Example 4B (411 mg, 1.30 mmol) in tetrahydrofuran (6 mL), and the mixture was stirred at 45°C for 1 hour, then EDCI (249.04 mg, 1.30 mmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 50 mL of water and extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 100 mL (50 mL×2) of aqueous solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography to obtain Example 4C, which was used directly in the next step without purification.
-
- Lithium hydroxide (139.33 mg, 3.32 mmol) was added to a solution of Example 4C (333 mg, 664.05 µmol) in tetrahydrofuran (4 mL) and water (2 mL), and the mixture was stirred at 20°C for 16 hours. The mixture was acidified with dilute hydrochloric acid (1N, 6mL) to pH=6, and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200mL (100mL×2) of saline solution, and dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by high performance liquid chromatography (TFA conditions) to obtain Example 4. 1H NMR (400MHz, DMSO-d6) δ = 7.79 (br d, J=8.4 Hz, 2H), 7.49 (br s, 4H), 7.29 - 7.21 (m, 3H), 6.95 - 6.78 (m, 2H), 6.08 (br d, J=7.0 Hz, 1H), 3.44 - 3.39 (m, 2H), 2.84 (br t, J=7.4 Hz, 2H), 1.96 (br d, J=6.7 Hz, 3H).
-
-
- Potassium carbonate (920.67 mg, 6.66 mmol) and (1R)-1-Phenylprop-1-amine (330.25 mg, 2.44 mmol, 350.58 µL) were added to a solution of methyl (E)-3-(4-fluoro-3-nitro-phenyl)acrylate (500 mg, 2.22 mmol) in tetrahydrofuran (10 mL), and the mixture was stirred at 50°C for 16 hours. The reaction mixture was diluted with water (20 mL) and then extracted with ethyl acetate (10 mL×3). The combined organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 5A, which was used directly in the next step without purification. 1H NMR (400MHz, CDCl3) δ= 8.67 (br d, J=5.8 Hz, 1H), 8.24 (d, J=2.1 Hz, 1H), 7.46 (d, J=15.9 Hz, 1H), 7.36 (dd, J=2.1, 9.0 Hz, 1H), 7.32 - 7.19 (m, 6H), 6.60 (d, J=9.0 Hz, 1H), 6.16 (d, J=15.9 Hz, 1H), 4.41 (q, J=6.5 Hz, 1H), 3.70 (s, 3H), 1.95 - 1.85 (m, 2H), 0.96 (t, J=7.4 Hz, 3H)
-
- To a solution of Example 5A (400 mg, 1.18 mmol) in tetrahydrofuran (5 mL), nickel dichloride hexahydrate (1.12 g, 4.70 mmol) was added and then a solution of sodium borohydride (88.92 mg, 2.35 mmol) in dimethylformamide (1 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 2 hours, then sodium borohydride (177.84 mg, 4.70 mmol) was added in batches at 0°C and stirred at 15°C 2 hours. The reaction mixture was diluted with water (20 mL) and then filtered. The filtrate was extracted with ethyl acetate (20 mL×4). The combined organic layer was washed with brine (40 mL×1), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 5B, which was used directly in the next step without purification.
-
- 4-(trifluoromethoxy)phenylthio isocyanate (270.12 mg, 1.23 mmol) was added to a solution of Example 5B (350 mg, 1.12 mmol) in tetrahydrofuran (5 mL), and the mixture was stirred at 25°C for 1 hour. Then EDCI (429.54 mg, 2.24 mmol) was added to the mixture and reacted at 70°C for 2 hours. The reaction mixture was concentrated under reduced pressure to remove tetrahydrofuran. The residue was diluted with water (10 mL) and extracted with ethyl acetate (10 mL×3). The combined organic layer was washed with HCl (1M, 5mL) and brine (20mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 5C, which was used directly in the next step without further purification.
-
- Lithium hydroxide monohydrate (126.52 mg, 3.02 mmol) was added to a solution of Example 5C (500 mg, 1.01 mmol) in water (5 mL), and the mixture was stirred at 20°C for 16 hours. The mixture was adjusted to pH 6-7 with HCl (1M aqueous solution), and extracted with ethyl acetate (10 mL×4). The combined organic layer was washed with brine (20m×1), dried with anhydrous sodium sulfate, and filtered and concentrated under reduced pressure to obtain the residue, which was separated and purified by high performance liquid chromatography (TFA conditions) to obtain Example 5. 1H NMR (400MHz, METHANOL-d4) δ= 7.67 - 7.60 (m, 2H), 7.56 - 7.43 (m, 6H), 7.42 - 7.36 (m, 1H), 7.32 (s, 1H), 7.08 (d, J=1.0 Hz, 2H), 5.84 (dd, J=5.5, 10.1 Hz, 1H), 2.98 (t, J=7.5 Hz, 2H), 2.76 - 2.65 (m, 1H), 2.65 - 2.54 (m, 3H), 1.06 (t, J=7.3 Hz, 3H).
-
-
- To a solution of methyl (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoate (800 mg, 3.55 mmol) in tetrahydrofuran (10 mL) was added (1R)-tetrahydronaphthalene-1-amine (523.04 mg, 3.55 mmol) and potassium carbonate (982.04 mg, 7.11 mmol), and the mixture was stirred at 50°C for 16 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saline solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 6A, which was used directly in the next step without purification.
-
- To a solution of Example 6A (1.31 g, 3.72 mmol) in methanol (10 mL) was added nickel chloride (4.42 g, 18.59 mmol), and then a solution of sodium borohydride (1.97 g, 52.05 mmol) dissolved in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 16 hours. The mixture was poured into water (100mL), ethyl acetate (40mL) and filtered through a pad of celite. The cake was washed with ethyl acetate (60 mL×3), and the mixture was extracted with 150 mL of ethyl acetate. The combined organic phase was washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain Example 6B, which was used directly in the next step without purification.
-
- To a solution of Example 6B (1.09 g, 2.99 mmol) in tetrahydrofuran (15 mL) was added isothiocyanoyl-4-(trifluoromethoxy)benzene (720.97 mg, 3.29 mmol), and the mixture was stirred at 50°C for 1 hour. Then EDCI (573.25 mg, 2.99 mmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saline solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 12:1) to obtain Example 6C.
-
- To a solution of Example 6C (1.36 g, 2.64 mmol) in tetrahydrofuran (10 mL) and water (4 mL) was added lithium hydroxide (554.44 mg, 13.21 mmol), and the mixture was stirred at 25°C for 16 hours. The mixture was acidified to pH=6 with dilute hydrochloric acid (1N, 4ml), and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saline solution, dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was dissolved in EA (10 mL) and stirred at 25 °C for 30 min, then the mixture was filtered and washed with ethyl acetate (2×10 mL) to obtain Example 6. 1H NMR (400MHz, METHANOL-d4) δ = 7.60 (br d, J=8.6 Hz, 2H), 7.33 - 7.15 (m, 5H), 7.04 (br t, J=7.0 Hz, 1H), 6.83 (br d, J=7.6 Hz, 1H), 6.74 (br d, J=7.9 Hz, 1H), 6.41 (br d, J=8.1 Hz, 1H), 5.88 (br t, J=8.1 Hz, 1H), 3.15 - 3.01 (m, 1H), 3.00 - 2.85 (m, 3H), 2.57 (br t, J=7.4 Hz, 2H), 2.30 (br s, 2H), 2.13 (br s, 1H), 2.01 (br d, J=16.1 Hz, 1H).
-
-
- To a solution of methyl (E)-3-(4-Fluoro-3-nitrophenyl)acrylate (0.5 g, 2.22 mmol) and (R)-1-(3-chlorophenyl)ethylamine (380.12 mg, 2.44 mmol) in tetrahydrofuran (10 mL) was added potassium carbonate (613.78 mg, 4.44 mmol), and the mixed solution was stirred at 50°C for 12 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography to obtain Example 7A as a yellow oil. 1H NMR (400MHz, CDCl3) δ= 8.49 (br d, J=5.5 Hz, 1H), 8.26 (d, J=2.1 Hz, 1H), 7.47 (d, J=15.9 Hz, 1H), 7.40 (dd, J=2.0, 9.0 Hz, 1H), 7.24 (s, 1H), 7.21 - 7.16 (m, 2H), 7.16 - 7.12 (m, 1H), 6.55 (d, J=9.0 Hz, 1H), 6.19 (d, J=15.9 Hz, 1H), 4.62 (quin, J=6.5 Hz, 1H), 3.71 (s, 3H), 1.59 (d, J=6.7 Hz, 3H).
-
- Under the protection of nitrogen gas, nickel chloride (1.42 g, 10.95 mmol) was added to a solution of Example 7A (0.79 g, 2.19 mmol) in methanol (10 mL), and after cooling to 0°C, sodium borohydride (828.40 mg, 21.90 mmol) was slowly added, and the mixed solution was stirred at 15°C for 0.5 hour. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution and stirring for 15 minutes. The reaction solution was extracted with ethyl acetate (50 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 7B as a yellow oil, which was used directly in the next step without further purification.
-
- To a solution of Example 7B (0.615g, 1.85mmol) in tetrahydrofuran (10mL) was added 4-(trifluoromethoxy)phenyl isothiocyanate (486.02 mg, 2.22 mmol, 360.01µL), the mixture was stirred at 40°C for 0.5 hour, then EDC·HCl (708.46 mg, 3.70 mmol) was added and stirred at 70°C for 5 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purification by column chromatography to obtain Example 7C as a yellow solid.
-
- Lithium hydroxide (234.96 mg, 5.60 mmol) was added to a mixed solution of Example 7C (0.58g, 1.12mmol) in tetrahydrofuran (5 mL) and water (5 mL), and stirred at 20°C for 16 hours. The reaction solution was adjusted to pH 6 with 1M hydrochloric acid, then diluted with 30 mL of water, and extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by high performance liquid chromatography to obtain Example 7. 1H NMR (400MHz, DMSO-d6) δ= 9.27 (s, 1H), 7.93 (d, J=9.0 Hz, 2H), 7.44 - 7.32 (m, 5H), 7.28 - 7.21 (m, 2H), 6.79 - 6.68 (m, 2H), 6.07 (q, J=6.9 Hz, 1H), 2.82 (br t, J=7.5 Hz, 2H), 2.53 (br s, 2H), 1.90 (d, J=7.0 Hz, 3H).
-
-
- To a solution of methyl (E)-3-(4-Fluoro-3-nitro-phenyl)prop-2-enoate (500 mg, 2.22 mmol) in THF (10mL) was added K2CO3 (920.67mg, 6.66mmol) and (1R)-Indan-1-amine (325.33 mg, 2.44 mmol, 312.81 µL). The mixture was stirred at 50°C for 16 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layer was washed with brine (20 mL×2), dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 8A. 1H NMR (400MHz, CDCl3) δ= 8.46 (br d, J=7.0 Hz, 1H), 8.29 (d, J=2.1 Hz, 1H), 7.60 (dd, J=2.1, 9.0 Hz, 1H), 7.54 (d, J=15.9 Hz, 1H), 7.31 - 7.19 (m, 4H), 7.18 - 7.11 (m, 1H), 7.05 (d, J=9.0 Hz, 1H), 6.26 (d, J=15.9 Hz, 1H), 5.15 (q, J=7.1 Hz, 1H), 3.73 (s, 3H), 3.08 - 2.99 (m, 1H), 2.96 - 2.86 (m, 1H), 2.70 - 2.60 (m, 1H), 2.02 - 1.96 (m, 1H).
-
- To a solution of Example 8A (720 mg, 2.13 mmol) in MeOH (20 mL) and DMF (5 mL), NiCl2·6H2O (2.02g, 8.51mmol) and NaBH4 (563.54mg, 14.90mmol) were added in batches. The mixture was stirred at 0°C for 1 hour. The reaction mixture was quenched by adding water (50 mL) and then diluted with ethyl acetate (50 mL). The mixture was filtered and extracted with ethyl acetate (30 mL×3). The combined organic layer was washed with brine (100 mL×1), dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 8B as a brown oil. The residue was used directly in the next step without further purification.
-
- To a solution of Example 8B (800 mg, 2.58 mmol) in THF (10 mL) was added 4-(trifluoromethoxy)phenyl isothiocyanate (677.91 mg, 3.09 mmol, 502.16 µL). The mixture was stirred at 30°C for 1 h. Then EDCI (988.19 mg, 5.15 mmol) was added and the mixture was stirred at 70°C for 2 hours. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layer was washed with brine (30 mL×1), dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography to obtain Example 8C as a brown oil. 1H NMR (400MHz, CDCl3) δ= 7.52 - 7.42 (m, 3H), 7.37 - 7.29 (m, 2H), 7.28 - 7.18 (m, 3H), 7.11 (br d, J=8.7 Hz, 2H), 7.03 - 6.93 (m, 1H), 6.06 (t, J=8.3 Hz, 1H), 3.70 (s, 3H), 3.30 - 3.20 (m, 1H), 3.16 - 3.09 (m, 1H), 3.06 (t, J=7.8 Hz, 2H), 2.82 - 2.73 (m, 1H), 2.70 (t, J=7.9 Hz, 2H), 2.34 (qd, J=8.8, 13.4 Hz, 1H).
-
- To a solution of Example 8C (450 mg, 908.19 µmol) in THF (2 mL) and H2O (2 mL) was added LiOH.H2O (114.33 mg, 2.72 mmol). The mixture was stirred at 20°C for 16 hours. The mixture was adjusted to pH 7 with aqueous HCl (1M), and then extracted with ethyl acetate (10 mL×3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure, and purified by high performance liquid chromatography to obtain Example 8. 1H NMR (400MHz, METHANOL-d4) δ = 7.73 - 7.59 (m, 2H), 7.56 - 7.47 (m, 3H), 7.46 - 7.40 (m, 1H), 7.32 - 7.20 (m, 3H), 6.96 (d, J=8.3 Hz, 1H), 6.41 - 6.22 (m, 2H), 3.40 - 3.34 (m, 1H), 3.20 (td, J=8.5, 16.6 Hz, 1H), 2.99 - 2.93 (m, 2H), 2.92 - 2.84 (m, 1H), 2.62 - 2.55 (m, 2H), 2.55 - 2.46 (m, 1H).
-
-
- To a solution of methyl (E)-3-(4-fluoro-3-nitrophenyl)acrylate (0.5g, 2.22mmol) and diphenylmethylamine (447.60mg, 2.44mmol, 422.26µL) in tetrahydrofuran (10mL), potassium carbonate (613.78mg, 4.44mmol) was added, and the mixed solution was stirred at 50°C for 12 hours. Then diphenylmethylamine (81.38 mg, 444.10 µmol, 76.77 µL) was added, and the solution was stirred at 55°C for 12 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography to obtain Example 9A as a yellow solid. 1H NMR (400MHz, CDCl3) δ= 8.74 (br d, J=5.3 Hz, 1H), 8.27 (d, J=1.9 Hz, 1H), 7.48 (d, J=15.9 Hz, 1H), 7.42 (dd, J=1.8, 8.9 Hz, 1H), 7.32 - 7.20 (m, 10H), 6.69 (d, J=9.0 Hz, 1H), 6.19 (d, J=15.9 Hz, 1H), 5.70 (d, J=5.5 Hz, 1H), 3.71 (s, 3H).
-
- Under the protection of nitrogen gas, nickel chloride (1.10 g, 8.50 mmol) was added to a solution of Example 9A (0.66 g, 1.70 mmol) in methanol (10 mL), and after cooling to 0°C, sodium borohydride (642.86 mg, 16.99 mmol) were added slowly. The mixed solution was stirred at 20°C for 0.5 hour. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution and stirring for 15 minutes. The reaction solution was extracted with ethyl acetate (50 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 9B as a yellow oil, which was used directly in the next step without purification.
-
- To a solution of Example 9B (0.41g, 1.14mmol) in tetrahydrofuran (10 mL), 4-(trifluoromethoxy)phenyl isothiocyanate (278 mg, 1.27 mmol, 205.93 µL) was added and stirred at 40°C for 1 hour. Then EDC·HCl (436.11 mg, 2.27 mmol) was added and stirred at 70°C for 12 hours. The reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 9C as a yellow solid.
-
- To a solution of Example 9C (0.46g, 843.18µmol) in tetrahydrofuran (5mL) and water (5mL), lithium hydroxide monohydrate (176.92mg, 4.22mmol) was added and stirred at 20°C for 12 hours. The reaction solution was adjusted to pH 6 with 1M hydrochloric acid, and extracted with ethyl acetate (20 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was diluted with 10 mL petroleum ether: ethyl acetate = 10:1, stirred for 30 minutes, filtered and concentrated under reduced pressure to obtain Example 9. 1H NMR (400MHz, DMSO-d6) δ= 12.06 (br s, 1H), 9.33 (br s, 1H), 7.90 (br d, J=8.2 Hz, 2H), 7.46 - 7.35 (m, 7H), 7.32 (br d, J=8.7 Hz, 2H), 7.26 (br s, 1H), 7.20 (br d, J=7.1 Hz, 4H), 6.64 (br d, J=7.8 Hz, 1H), 6.28 (br d, J=8.2 Hz, 1H), 2.81 (br t, J=7.5 Hz, 2H), 2.53 (br s, 2H).
-
-
- To a solution of methyl (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoate (750 mg, 3.33 mmol) in tetrahydrofuran (10 mL), potassium carbonate (920.67 mg, 6.66 mmol)) and (1R)-1-(2-methoxyphenyl)ethylamine (503.52 mg, 3.33 mmol) were added, and the mixture was stirred at 50°C for 16 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saline solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue, and the residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 15:1) to obtain Example 10A.
-
- To a solution of Example 10A (1.19 g, 3.34 mmol) in methanol (10 mL), nickel chloride (3.97 g, 16.70 mmol) was added, and then a solution of sodium borohydride (1.39 g, 36.73 mmol) in dimethylformamide (5 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 16 hours. The mixture was poured into water (100 mL), and ethyl acetate (40 mL) and filtered through a pad of celite. The filter cake was washed with ethyl acetate (60 mL×3) and the filtrate was extracted with 150 mL of ethyl acetate. The combined organic phases was washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 10B.
-
- To a solution of Example 10B (1.11g, 3.35mmol) in tetrahydrofuran (15 mL), 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (734.27 mg, 3.35 mmol, 543.90 µL) was added, and the mixture was stirred at 50°C for 1 hour, then EDCI (642.11 mg, 3.35 mmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saturated saline solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 6:1) to obtain Example 10C.
-
- To a solution of Example 10C (1.32 g, 2.49 mmol) in tetrahydrofuran (6 mL) and water (3 mL), lithium hydroxide monohydrate (523.12 mg, 12.47 mmol) was added and the mixture was stirred at 25°C for 16 hours. The mixture was acidified with dilute hydrochloric acid (1N, 4ml) to pH=6, and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saturated saline solution, and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was dissolved in a mixed solution of ethyl acetate (4 mL) and petroleum ether (8 mL) and stirred at 25°C for 60 minutes. The mixture was filtered and the filter cake was washed with a mixed solution of ethyl acetate (1 mL) and petroleum ether (2 mL), to obtain Example 10. 1H NMR (400MHz, CDCl3) δ = 7.60 - 7.55 (m, 2H), 7.37 - 7.32 (m, 1H), 7.28 - 7.22 (m, 3H), 7.09 - 7.03 (m, 3H), 6.98 (dd, J=1.5, 8.3 Hz, 1H), 6.86 (d, J=8.3 Hz, 1H), 5.78 (q, J=7.1 Hz, 1H), 3.70 (s, 3H), 3.13 - 2.98 (m, 2H), 2.75 - 2.61 (m, 2H), 1.88 (d, J=7.1 Hz, 3H).
-
-
- To a solution of methyl (E)-3-(4-Fluoro-3-nitro-phenyl)prop-2-enoate (220 mg, 977.03 µmol) in tetrahydrofuran (10 mL), potassium carbonate (675.15 mg, 2.931 mmol) and (1R)-2,2-dimethyl-1-phenyl-prop-1-amine hydrochloride (195.13mg, 977.03µmol) were added. The mixture was stirred at 60°C for 48 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL (100 mL×2) of ethyl acetate. The combined organic layer was washed with 200 mL (100 mL×2) of saturated saline solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 12:1) to obtain Example 11A.
-
- To a solution of Example 11A (420 mg, 1.14 mmol) in methanol (6 mL), nickel chloride (1.35 g, 5.70 mmol) was added and then a solution of sodium borohydride (474.42 mg, 12.54 mmol) in dimethylformamide (3 mL) was added dropwise, while controlling the internal temperature not to exceed 10°C, and then the reaction mixture was stirred at 10°C for 2 hours. The mixture was poured into water (80 mL), ethyl acetate (20 mL) and filter through a pad of celite. The filter cake was washed with ethyl acetate (50 mL×3), and the mixture was extracted with 100 mL of ethyl acetate. The combined organic phase was washed with saturated brine (80 mL×2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 11B, which was used directly in the next step without purification.
-
- To a solution of Example 11B (270 mg, 793.05 µmol) in tetrahydrofuran (5 mL), 1-isothiocyanato-4-(trifluoromethoxy)benzene (173.82 mg, 793.05 µmol, 128.76 µL) was added and the mixture was stirred at 50°C for 1 hour, then EDCI (167.23 mg, 872.35 µmol) was added and the mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with 100 mL of water and extracted with 200 mL of ethyl acetate (100 mL×2). The combined organic layer was washed with 200 mL of saturated saline solution (100 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 10:1) to obtain Example 11C.
-
- To a solution of Example 11C (373 mg, 695.52 µmol) in tetrahydrofuran (3 mL) and water (1 mL), lithium hydroxide (145.93 mg, 3.48 mmol) was added, and the mixture was stirred at 25°C for 6 hours. The mixture was acidified to pH=6 with dilute hydrochloric acid (1 N, 3 ml), filtered, and the filter cake was washed with 20 mL of ethyl acetate to obtain a residue. The filter cake was dissolved in methanol (10 mL) and dichloromethane (10 mL), the mixture was stirred at 80°C for 1 hour, and then filtered. The filter cake was the product Example 11. 1H NMR (400MHz, DMSO-d6) δ = 9.17 (s, 1H), 7.96 (br d, J=9.0 Hz, 2H), 7.62 (br d, J=7.6 Hz, 2H), 7.41 - 7.33 (m, 4H), 7.31 - 7.25 (m, 1H), 7.18 (s, 1H), 6.76 (d, J=8.3 Hz, 1H), 6.63 (dd, J=1.4, 8.4 Hz, 1H), 5.86 (s, 1H), 2.78 (br t, J=7.6 Hz, 2H), 2.47-2.52(m, 2H), 1.22 (s, 9H).
-
-
- Methyl (E)-3-(4-Fluoro-3-nitro-phenyl)prop-2-enoate (0.26 g, 1.15 mmol) was dissolved in acetonitrile (10 mL), then potassium carbonate (558.55 mg, 3.45 mmol) and (R)-cyclopropyl(phenyl)methylamine hydrochloride (233.30 mg, 1.27 mmol) were added and stirred at 80°C for 2 hours. The reaction mixture was diluted with 100 mL of water and extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 50 mL (50 mL×1) of brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, and purified by column chromatography to obtain Example 12 as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 0.34 - 0.56 (m, 2 H), 0.60 - 0.80 (m, 2 H), 1.30 - 1.43 (m, 1 H), 3.78 (s, 3 H), 4.04 (dd, J=7.95, 5.38 Hz, 1 H), 6.23 (d, J=15.89 Hz, 1 H), 6.56 (d, J=8.93 Hz, 1 H), 6.52 - 6.62 (m, 1 H), 7.27 - 7.42 (m, 6 H), 7.53 (d, J=15.89 Hz, 1 H), 8.32 (d, J=2.08 Hz, 1 H), 8.88 (br d, J=5.01 Hz, 1 H).
-
- To Example 12A (388 mg, 1.10 mmol) and nickel chloride hexahydrate (1.31 g, 5.51 mmol), MeOH (6 mL) and THF (6 mL) were added, and sodium borohydride (416.54 mg, 11.01 mmol) was added in batches at 5°C, and stirred at 5°C for 0.5 hours. The reaction mixture was quenched by adding 100 mL of water, filtered, and the filtrate was extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 50 mL (50 mL×1) of brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 12B.
-
- To a solution of Example 12B (280 mg, 863.09 µmol) in THF (15 mL), isothiocyanoyl-4-(trifluoromethoxy)benzene (227.01 mg, 1.04 mmol, 168.16 µL) was added. After the addition, the mixture was stirred at 40°C for 1 hour, and then EDCI (330.91 mg, 1.73 mmol) was added and stirred at 70°C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove THF, diluted with 80 mL of water and extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 50 mL (50 mL×1) of brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure, and purified by column chromatography to obtain Example 12C as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 0.47 - 0.70 (m, 3 H), 0.95 - 1.07 (m, 1 H), 1.74 - 1.83 (m, 1 H), 2.70 (t, J=7.89 Hz, 2 H), 3.06 (t, J=7.95 Hz, 2 H), 3.69 (s, 3 H), 4.84 (d, J=9.54 Hz, 1 H), 6.97 (dd, J=8.19, 1.34 Hz, 1 H), 7.05 - 7.16 (m, 3 H), 7.28 - 7.33 (m, 2 H), 7.40 - 7.54 (m, 6 H).
-
- To a solution of Example 12C (0.29 g, 569.16 µmol) in THF (3 mL), MeOH (3 mL) and H2O (3 mL), lithium hydroxide monohydrate (119.41 mg, 2.85 mmol) was added and stirred at 20°C for 16 hours. The reaction mixture was slowly adjusted to pH=4 with 1N HCl solution, and extracted with ethyl acetate (40 mL×2). The combined organic layer was washed with 50 mL of brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, stirred with MeOH (10 mL), filtered, and dried under vacuum to obtain Example 12. 1H NMR (400 MHz, CDCl3) δ = 4.38 (br s, 1 H), 4.79 - 4.97 (m, 1 H), 6.51 - 6.62 (m, 2 H), 7.25 - 7.27 (m, 1 H), 7.27 - 7.29 (m, 1 H), 7.38 - 7.51 (m, 5 H).
-
-
- 3,3-Dimethylinden-1-one (3 g, 18.73 mmol) was dissolved in toluene (40 mL), into which titanium tetraisopropoxide (10.64 g, 37.46 mmol, 11.05 mL) and 2-methylpropane-2-sulfinamide (2.72 g, 22.48 mmol) were added, stirred at 60°C for 24 hours, then 2-methylpropane-2-sulfinamide (2.72 g, 22.48 mmol) and titanium tetraisopropoxide (5.32 g, 18.73 mmol, 5.53mL) were further added and stirred at 110°C for 16 hours. The reaction mixture was quenched by adding 200 mL of water, and then filtered. The filtrate was extracted with 160 mL (80 mL×2) of ethyl acetate. The combined organic layer was washed with 80 mL (80 mL×1) of brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure, and purified by column chromatography to obtain compound Example 13A as a brown oil. 1H NMR (400 MHz, CDCl3) δ = 1.29 - 1.43 (m, 15 H) 2.98 (d, J=19.07 Hz, 1 H) 3.34 (d, J=19.20 Hz, 1 H) 7.29 - 7.42 (m, 2 H) 7.48 - 7.58 (m, 1 H) 7.76 (d, J=7.70 Hz, 1 H).
-
- Example 13A (1.4 g, 5.32 mmol) was dissolved in THF (20 mL) and water (574.67 mg, 31.89 mmol, 574.67 µL), into which sodium borohydride (1.01 g, 26.58 mmol) was added, and the mixture was stirred at 25°C for 4 hours. The reaction mixture was quenched by adding 100 mL of water, and then extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 50 mL of saturated saline solution, dried over sodium sulfate, filtered and concentrated under reduced pressure, and purified by column chromatography to obtain compound Example 13B as a white solid. 1H NMR (400 MHz, CDCl3) δ = 1.21 - 1.28 (m, 12 H) 1.38 (s, 3 H) 1.88 (dd, J=12.84, 7.46 Hz, 1 H) 2.37 (dd, J=12.84, 7.21 Hz, 1 H) 3.49 (br d, J=6.60 Hz, 1 H) 4.88 - 4.99 (m, 1 H) 7.14 - 7.21 (m, 1 H) 7.23 - 7.29 (m, 2 H) 7.51 - 7.60 (m, 1 H).
-
- To a solution of Example 13B (810 mg, 3.05 mmol) in MeOH (8 mL), HCl/dioxane (4M, 3mL) was added and stirred at 20°C for 0.5 hours. The mixture was diluted with methyl tert-butyl ether (15 mL) and stirred at 25°C for 30 minutes, filtered, and dried in vacuum to obtain Example 13C as a white solid. 1H NMR (400 MHz, METHANOL-d4) δ = 1.15 - 1.30 (m, 3 H) 1.40 - 1.50 (m, 3 H) 1.93 (dd, J=13.02, 8.13 Hz, 1 H) 2.53 (dd, J=12.96, 7.70 Hz, 1 H) 3.31 (dt, J=3.30, 1.65 Hz, 1 H) 7.21 - 7.59 (m, 4 H).
-
- To a solution of methyl (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoate (400 mg, 1.78 mmol) in THF (12mL), potassium carbonate (982.04mg, 7.11mmol) and Example 13C (491.69mg, 2.49mmol) were added and stirred at 65°C for 16 hours. The mixture was diluted with 100 mL of water and extracted with 120 mL (60 mL×2) of ethyl acetate. The combined organic layer was washed with 50 mL (50 mL×1) of brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, and purified by column chromatography to obtain Example 13D as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 1.33 (s, 3 H) 1.43 (s, 3 H) 1.95 (dd, J=12.72, 7.34 Hz, 1 H) 2.60 (dd, J=12.65, 7.15 Hz, 1 H) 3.82 (s, 3 H) 5.25 (q, J=7.21 Hz, 1 H) 6.34 (d, J=15.89 Hz, 1 H) 7.14 (d, J=9.05 Hz, 1 H) 7.25 - 7.27 (m, 1 H) 7.27 - 7.29 (m, 1 H) 7.30 - 7.39 (m, 2 H) 7.57 - 7.73 (m, 2 H) 8.38 (d, J=2.20 Hz, 1 H) 8.57 (br d, J=7.09 Hz, 1 H)
-
- Example 13D (300 mg, 818.75 µmol) was dissolved in THF (5mL) and MeOH (5mL), into which Pd/C (50mg, 10%) was added, the atmosphere was replaced with hydrogen gas for 3 times, and the mixture was stirred at 25 °C under H2 (15psi) for 16 hours. After filtration, the filtrate was concentrated under reduced pressure to obtain Example 13E as a brown oil.
-
- Example 13E (255 mg, 753.45 µmol) was dissolved in THF (8 mL), into which 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (198.17 mg, 904.14 µmol, 146.79 µL) was added and stirred at 40°C for 1 hour, then EDCI (288.87 mg, 1.51 mmol) was added and stirred at 70°C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove THF, diluted with 80 mL of water and extracted with 100 mL (50 mL×2) of ethyl acetate. The combined organic layer was washed with 50 mL (50 mL×1) of brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, and purified by column chromatography, and then sujectd to chiral resolution to obtain Example 13F as a white solid compound. 1H NMR (400 MHz, CDCl3) δ =1.28 - 1.55 (m, 6 H) 2.14 - 2.72 (m, 4 H) 3.06 (br s, 2 H) 3.69 (s, 3 H) 5.50 (br s, 1 H) 6.06 (br s, 1 H) 6.92 - 7.60 (m, 11 H).
-
- To a solution of Example 13F (180 mg, 343.81 µmol) in MeOH (2M1), lithium hydroxide monohydrate (43.28 mg, 1.03 mmol), THF (2mL) and H2O (2 mL) were added and stirred at 25°C for 1 hour. The reaction mixture was slowly adjusted to pH=4 with 1N HCl, and then the precipitate was collected by filtration and dried under vacuum to obtain Example 13. 1H NMR (400 MHz, METHANOL-d4) δ =1.34 (s, 3 H) 1.54 (s, 3 H) 2.37 (dd, J=12.65, 9.48 Hz, 1 H) 2.48 - 2.63 (m, 3 H) 2.90 (br t, J=7.58 Hz, 2 H) 6.05 - 6.37 (m, 2 H) 6.69 (br d, J=8.07 Hz, 1 H) 6.93 (br d, J=7.58 Hz, 1 H) 7.14 - 7.32 (m, 4 H) 7.35 - 7.42 (m, 2 H) 7.59 (br d, J=7.58 Hz, 2 H).
-
-
- A dry bottle was filled with 1-(trifluoromethyl)-1,2-benzoiodo-3-one (3.28 g, 10.37 mmol) and CuBr (123.96 mg, 864.15 µmol, 26.32 µL). The bottle was evacuated and backfilled with nitrogen gas for three times. Then, azido(trimethyl)silane (2.49 g, 21.60 mmol, 2.84 mL) and styrene (900 mg, 8.64 mmol) dissolved in ACN (40 mL) were added to the above bottle. The reaction mixture was stirred at 40°C for 1.5 hours. The reaction mixture was diluted with water (40 mL) and extracted with DCM (20 mL×3). The combined organic layer was washed with brine (20 mL×1), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography to obtain Example 14A as a colorless oily compound. 1H NMR (400MHz, CDCl3) δ= 7.50 - 7.36 (m, 5H), 4.81 (dd, J=5.1, 8.4 Hz, 1H), 2.73 - 2.45 (m, 2H).
-
- To a solution of Example 14A (1.1g, 5.11mmol) in MeOH (15mL), CuSO4 (81.59 mg, 511.21 µmol, 78.46 µL) and NaBH4 (290.11 mg, 7.67 mmol) were added. The mixture was stirred at 0°C for 1 h and then at 20°C for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layer was washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain Example 14B as a brown oil, which was used in the next step without further purification.
-
- To a solution of methyl (E)-3-(4-fluoro-3-nitro-phenyl)prop-2-enoate (600 mg, 2.66 mmol) in THF (10mL), K2CO3 (1.10 g, 7.99 mmol) and Example 14B (720 mg, 3.81 mmol) were added. The mixture was stirred at 50°C for 16 hours. The mixture was then stirred at 70°C for 32 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain the crude product Example 14C as a yellow oil, which was used in the next step without further purification.
-
- To a solution of Example 14C (1 g, 2.54 mmol) in MeOH (20 mL), NiCl2·6H2O (2.41 g, 10.14 mmol) was added, and then NaBH4 (959.38 mg, 25.36 mmol) was added in portions at 0°C, and the mixture was kept at 0°C for 1 hour. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layer was washed with brine (50 mL×1), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain Example 14D as a brown oily residue, which was used directly in the next step without further purification.
-
- To Example 14D (770 mg, 2.10 mmol) in THF (20 mL), 1-isothiocyanoyl-4-(trifluoromethoxy)benzene (552.78 mg, 2.52 mmol, 409.47 µL) was added. The mixture was stirred at 40°C for 1 h. Then EDCI (805.79 mg, 4.20 mmol) was added and the mixture was stirred at 70°C for 2 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (30 mL×3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography to obtain a residue. The residue was separated by SFC (chiral column: Chiralcel OD-3 50×4.6mm ID, 3µm; mobile phase: A: CO2, B: methanol (containing 0.05% DEA); gradient: methanol 5% to 40%; flow rate: 3 mL per minute; wavelength: 220 nm) to obtain Example 14E (retention time RT=1.546 minutes) and Example 14F (retention time RT=1.941 minutes).
-
- To a solution of Example 14E (220 mg, 398.93 µmol) in MeOH (3 mL) and H2O (3 mL), LiOH.H2O (50.22 mg, 1.20 mmol) was added. The mixture was stirred at 30°C for 16 h. The mixture was stirred at 30°C for another 3 hours. The mixture was adjusted to pH 5-6 with HCl (1M) solution to precipitate a solid, which was filtered and dried to obtain Example 14. 1H NMR (400MHz, METHANOL-d4) δ= 7.57 - 7.47 (m, 2H), 7.43 (d, J=4.4 Hz, 4H), 7.38 - 7.33 (m, 1H), 7.30 (s, 1H), 7.25 (d, J=8.3 Hz, 2H), 6.88 (d, J=0.6 Hz, 2H), 6.30 (dd, J=3.6, 10.5 Hz, 1H), 3.61 - 3.37 (m, 2H), 2.96 (t, J=7.7 Hz, 2H), 2.61 (t, J=7.7 Hz, 2H).
- To a solution of Example 14F (300 mg, 543.99 µmol) in MeOH (4 mL) and H2O (4 mL), LiOH·H2O (68.48 mg, 1.63 mmol) was added. The mixture was stirred at 30°C for 16 hours. The mixture was adjusted to pH 5-6 with HCl (1M) solution to precipitate a solid, which was filtered and dried to obtain Example 15. 1H NMR (400MHz, METHANOL-d4) δ = 7.55 - 7.49 (m, 2H), 7.43 (d, J=4.4 Hz, 4H), 7.38 - 7.33 (m, 1H), 7.30 (s, 1H), 7.28 - 7.21 (m, 2H), 6.87 (s, 2H), 6.30 (dd, J=3.5, 10.5 Hz, 1H), 3.56 - 3.41 (m, 2H), 2.96 (t, J=7.6 Hz, 2H), 2.61 (t, J=7.7 Hz, 2H).
- The IDH1 mutant catalyzes the NADPH-dependent reduction of α-KG (a-ketoglutarate) to 2-HG (2-hydroxyglutarate), and the consumed NADPH can be read by fluorescence.
- Basic reaction buffer: 50 mM KH2PO4, pH 7.5, 10 mM MgCl2, 10% glycerol, 150 mM NaCl, 0.05% BSA (bovine serum albumin), 2mM b-ME (2-mercaptoethanol), 0.003% Brij35 (polyethylene glycol lauryl ether)
- IDHlwt (wild type): 65 µM isocitrate + 50 µM NADP
- IDH1(R132H): 1500 µM α-KG + 15µM NADPH
- IDH1(R132C): 500µM α-KG + 15µM NADPH
- 1.33X enzyme (no enzyme in the control well), buffer, and NADP or NADPH (control well) were added into the wells of the reaction plate. The test compound was dissolved in 100% DMSO and then added to the enzyme mixture (Echo550, nanoliter level), and incubated for 60 minutes after simple centrifugation. A mixture of 4X substrate and cofactor were added to start the reaction. After simple centrifugation, the plate was incubated under shaking at room temperature for 45 minutes. A mixture of 3X lipoamide dehydrogenase and Resazurin was prepared, added to the reaction solution to test the amount of NADPH generated or remaining, and incubated at room temperature for 10 minutes after simple centrifugation. Multifunctional microplate reader Envision was used to measure (Ex/Em =535/590nm).
- The experimental results are shown in Table 1 and Table 2:
Table 1 IDH1 in vitro enzyme (IDH1R132H) activity IC50 test results Example Structure IDH1 R132H (nM) Example 1 7.9 Example 2 464.5 Example 3 320 Example 4 125.5 Example 5 89.53 Example 6 3.94 Example 7 121.1 Example 8 2.88 Example 9 21.9 Example 10 343.6 Example 11 24.5 Example 12 15.69 Table 2 IDH1 in vitro enzyme (IDH1 R132C, WT) activity IC50 test results Example Structure IDH1 R132C (nM) IDH1 WT (nM) Example 1 101.8 >10000 Example 6 12.79 >10000 - Conclusion: At the enzymatic level, the compounds of the present disclosure have a good inhibitory effect on the mutant IDH1R132H and IDH1R132C, and at the same time have no inhibitory effect on the wild-type IDH protein.
- In this study, the compound was incubated with the IDH1 mutant cell line, and the 2HG content in the cell culture supernatant was detected by LC-MS to determine the inhibitory activity of the compound on the IDH1 mutant. IDH1 catalyzes the reduction of isocitrate to α-ketoglutarate (a-KG) in organisms, and the IDH1 mutant further catalyzes the reduction of α-KG to 2-hydroxyglutarate (2HG).
- The U87MG-IDH1-R132H cell strain is a stable transfected cell strain that can stably express IDH1-R132H mutant, obtained via screening by transfecting U87MG cells with IDH1-R132H, and the HT1080 cell strain contains an endogenous IDH1-R132C mutant.
- The experimental process is as follows:
- 1) The compound was diluted 3-fold with DMSO and then added to the cell culture plate, at a total of 10 concentrations, double duplicate holes for each concentration. The negative control well contains only DMSO, and the positive control well contained BAY1436032 at a final concentration of 5µM. The final concentration of DMSO in all wells was 0.5%.
- 2) The IDH1 mutant cell line was seeded into a cell culture plate containing the compound at a density of 40,000 cells/well. The cells were incubated with the compound in a incubator at 37°C, 5% CO2 for 3 days.
- 3) After 3 days, 10 µl of cell culture supernatant was taken and diluted 21 folds with 200 µl ddH2O water to 210 µl and mixed well, from which 50µl diluted solution was taken and 200 µl precipitant (acetonitrile containing 0.4 µg/ml D-2-hydroxyglutaric acid 13C5) was added. After centrifugation at 4000 rpm for 10 minutes, 100 µl of supernatant was taken for detecting the content of 2-HG by LC-MS.
- 4) At the same time, the ATPlite 1Step kit was used to detect the effect of the compound on the cell viability of the IDH1 mutant cell strain according to the instructions.
- 5) 2HG content data was used to calculate the percentage of inhibition rate (inhibition rate %) of each concentration of compound against IDH1 mutant by the following calculation formula:
cell viability data was used to calculate the cytotoxicity percentage (cytotoxicity%) of the compound against IDH1 mutant cell strain by the following calculation formula:- CPD: signal of compound wells
- ZPE: average signal of negative control wells, with 0.5% DMSO instead of compound
- HPE: average signal of positive control wells
- 6) The inhibition rate% and cytotoxicity% were fitted with GraphPad Prism software to the dose-effect curve, to obtain the IC50 value of the test compound.
-
- Conclusion: At the cellular level, the compounds of the present disclosure have a good 2-HG inhibitory effect on U87MG brain glioma cells with IDH1R132H mutation.
- Test the pharmacokinetic parameters of the compound of the present disclosure in mice
- Experimental scheme:
- 1) Experimental drug: Example 6;
- 2) Experimental animals: 8 male CD-1 mice aged 7-10 weeks, divided into 2 groups, 4 in each group;
- 3) Drug preparation: for the tail vein injection group, an appropriate amount of the drug was weighted, and dissolved in a mixed solvent of DMSO: 20% hydroxypropyl betacyclodextrin (HPbCD) = 10: 90 to prepare a 0.5 mg/mL solution; for the intragastric administration group, an appropriate amount of the drug was weighted, and dissolved in DMSO: polyoxyethylene castor oil EL (Cremophor EL):5% sulfobutyl cyclodextrin (Captisol) = 5:10:85 to prepare a suspension.
- Animals in group 1 were given a single injection of the drug at a dose of 1 mg/kg and a concentration of 0.5 mg/mL via tail vein, and animals in group 2 were given a compound at a dose of 20 mg/kg and a concentration of 2 mg/mL via gavage. Plasma samples were cross-collected from the animals at 0.0833 (tail vein injection group only), 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after administration. The LC-MS/MS method was used to determine the drug concentration in the plasma sample, and the kinetic parameters of the tested drug are shown in Table 4:
Table 4 Pharmacokinetic evaluation parameters in mice Tail vein injection group Clearance Initial concentration Volume of distribution Half-life Area under curve Cl C0 (nM) Vd (L/Kg) T1/2 (h) AUC (mL/min/kg) 0-last(nM•h) 2.17 3541 0.690 2.90 15463 Intragastric administration group Highest concentration Time of highest concentration Area under curve Bioavailability Cmax(nM) T1/2(h) AUC0-last (nM•h) F (%) 33350 1.00 306609 99.1 - Conclusion: Example 6 of the present disclosure has good pharmacokinetic properties in mice.
Claims (16)
- A compound as shown in formula (I),R1 is selected from C1-6 alkyl, C3-6 cycloalkyl and phenyl, the C1-6 alkyl, C3-6 cycloalkyl and phenyl being optionally substituted with 1, 2 or 3 Ra;R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, C1-6 alkyl and C1-6 alkoxy, the C1-6 alkyl and C1-6 alkoxy being optionally substituted with 1, 2 or 3 Rb;alternatively, R1 and R2 are joined together to form a C4-6 cycloalkenyl optionally substituted with 1, 2 or 3 Rc;L is selected from -CH2CH2- and -C3-6 cycloalkyl-CH2-;n is selected from 1, 2 and 3; andRa, Rb, and Rc are each independently selected from F, Cl, Br, I, OH, NH2, CN, COOH, and Me;or an isomer thereof, or a pharmaceutically acceptable salt thereof.
- The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is selected from C1-3 alkyl, cyclopropanyl and phenyl, the C1-3 alkyl, cyclopropanyl and phenyl being optionally substituted with 1, 2 or 3 Ra.
- The compound or an isomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, C1-3 alkyl and C1-3 alkoxy, the C1-3 alkyl and C1-3 alkoxy being optionally substituted with 1, 2 or 3 Rb.
- The compound or an isomer thereof or a pharmaceutically acceptable salt thereof according to claim 4, wherein R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, CH3 and CH3O, the CH3 and CH3O being optionally substituted with 1, 2 or 3 Rb.
- The compound or an isomer thereof or a pharmaceutically acceptable salt thereof according to claim 5, wherein R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, COOH, CH3, CH2F, CHF2, CF3 and OCH3.
- The compound or an isomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, which is selected fromE is selected from -CH2-, -CH2CH2-, -C(CH3)2- and -C(CH3)2CH2-;R1 is as defined in any one of claims 2 to 3; andR2 and R3 are as defined in any one of claims 4 to 6.
- Use of the compound or an isomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15 in the manufacture of a medicament for treating a disease related to IDH1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810672394 | 2018-06-26 | ||
PCT/CN2019/092997 WO2020001474A1 (en) | 2018-06-26 | 2019-06-26 | Benzimidazole derivatives and use thereof as idh1 inhibitors |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3816158A1 true EP3816158A1 (en) | 2021-05-05 |
EP3816158A4 EP3816158A4 (en) | 2022-01-26 |
EP3816158B1 EP3816158B1 (en) | 2023-10-25 |
EP3816158C0 EP3816158C0 (en) | 2023-10-25 |
Family
ID=68986184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19827510.9A Active EP3816158B1 (en) | 2018-06-26 | 2019-06-26 | Benzimidazole derivatives and use thereof as idh1 inhibitors |
Country Status (9)
Country | Link |
---|---|
US (1) | US11407717B2 (en) |
EP (1) | EP3816158B1 (en) |
JP (1) | JP7258059B2 (en) |
KR (1) | KR102584855B1 (en) |
CN (1) | CN112533903B (en) |
AU (1) | AU2019296173B2 (en) |
CA (1) | CA3104760C (en) |
EA (1) | EA202190009A1 (en) |
WO (1) | WO2020001474A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4083023A4 (en) * | 2019-12-23 | 2023-11-15 | KPC Pharmaceuticals, Inc. | Salt form and crystal form of mutant idh1 inhibitor and preparation method therefor |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007514794A (en) * | 2003-12-19 | 2007-06-07 | メルク エンド カムパニー インコーポレーテッド | Cyclic guanidines, compositions containing such compounds, and methods of use |
WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
MX2010001340A (en) * | 2007-07-31 | 2010-06-02 | Schering Corp | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment. |
WO2009059214A1 (en) * | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
EP2297117B1 (en) * | 2008-05-19 | 2012-10-31 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
WO2012174312A2 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
PE20141581A1 (en) | 2011-09-27 | 2014-11-14 | Novartis Ag | 3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF MUTANT HDI |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
CN105980365B (en) * | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | Benzimidazolyl-2 radicals-amine as mIDH1 inhibitor |
MX2016010474A (en) * | 2014-02-11 | 2016-10-31 | Bayer Pharma AG | Benzimidazol-2-amines as midh1 inhibitors. |
CN107428690B (en) * | 2014-12-22 | 2021-04-13 | 美国政府健康及人类服务部 | Mutant IDH1 inhibitors useful for the treatment of cancer |
WO2016171756A1 (en) * | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
WO2017009325A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
EP3121166A1 (en) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
ES2764523T3 (en) | 2015-07-27 | 2020-06-03 | Lilly Co Eli | 7-Phenylethylamino-4H-pyrimido [4,5-D] [1,3] oxazin-2-one compounds and their use as mutant IDH1 inhibitors |
TW201718513A (en) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | Method for preparing substituted 3-(2-anilino-1-cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives |
WO2018010142A1 (en) | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
CA3029343C (en) * | 2016-07-21 | 2021-02-09 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof |
BR112019001732A2 (en) * | 2016-07-29 | 2019-05-07 | Flx Bio, Inc. | chemokine receptor modulators and uses thereof |
CN109983014B (en) | 2016-10-11 | 2022-12-23 | 艾科生物科技有限公司 | Mutant isocitrate dehydrogenase inhibitors, compositions and methods thereof |
-
2019
- 2019-06-26 US US17/254,890 patent/US11407717B2/en active Active
- 2019-06-26 KR KR1020217001715A patent/KR102584855B1/en active IP Right Grant
- 2019-06-26 JP JP2020573027A patent/JP7258059B2/en active Active
- 2019-06-26 CA CA3104760A patent/CA3104760C/en active Active
- 2019-06-26 EA EA202190009A patent/EA202190009A1/en unknown
- 2019-06-26 AU AU2019296173A patent/AU2019296173B2/en active Active
- 2019-06-26 EP EP19827510.9A patent/EP3816158B1/en active Active
- 2019-06-26 WO PCT/CN2019/092997 patent/WO2020001474A1/en unknown
- 2019-06-26 CN CN201980039036.1A patent/CN112533903B/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4083023A4 (en) * | 2019-12-23 | 2023-11-15 | KPC Pharmaceuticals, Inc. | Salt form and crystal form of mutant idh1 inhibitor and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
JP2021529200A (en) | 2021-10-28 |
KR102584855B1 (en) | 2023-10-05 |
US20210206728A1 (en) | 2021-07-08 |
KR20210022078A (en) | 2021-03-02 |
CA3104760C (en) | 2023-09-26 |
WO2020001474A1 (en) | 2020-01-02 |
EP3816158B1 (en) | 2023-10-25 |
CN112533903B (en) | 2022-08-16 |
AU2019296173B2 (en) | 2022-01-06 |
AU2019296173A1 (en) | 2021-02-04 |
JP7258059B2 (en) | 2023-04-14 |
EP3816158A4 (en) | 2022-01-26 |
CA3104760A1 (en) | 2020-01-02 |
CN112533903A (en) | 2021-03-19 |
EP3816158C0 (en) | 2023-10-25 |
EA202190009A1 (en) | 2021-03-25 |
US11407717B2 (en) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4166142A1 (en) | Methyl-substituted benzobisoxazole compound and use thereof | |
EP2773644B1 (en) | Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase | |
KR920002603A (en) | Pyrazolo pyridine compound and preparation method thereof | |
JP7165270B2 (en) | Compounds for retinal diseases | |
KR20240031347A (en) | Azetidinyl pyrimidine and its uses | |
JP2022547390A (en) | VMAT2 inhibitor, its preparation method, and its use | |
EP3816158B1 (en) | Benzimidazole derivatives and use thereof as idh1 inhibitors | |
JP7395762B2 (en) | Use of JAK inhibitors in the preparation of drugs for the treatment of JAK kinase-related diseases | |
EP3919477A1 (en) | Fluorovinylbenzamide compound as pd-l1 immunomodulator | |
US20230312504A1 (en) | Quinoline compounds | |
US11760751B2 (en) | Benzo 2-azaspiro[4.4]nonane compound and use thereof | |
EP4144741A1 (en) | Pyrimidine-based tricyclic compound and use thereof | |
EA040879B1 (en) | Benzimidazole derivatives and their use as IDH1 inhibitors | |
WO2021233349A1 (en) | Pyridine derivative and application thereof | |
TW201000096A (en) | Four-membered ring-condensed pyrrolidine derivatives, and preparation method and medical use thereof | |
WO1999031097A1 (en) | Imidazol derivatives as muscarinic m3 receptor antagonists | |
WO2014062204A1 (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | |
JPS625968A (en) | Novel n-substituted 3,4-dihydropyrimidine derivative and remedy for circulatory disease | |
AU2022365972A1 (en) | Pyrimidine tricyclic derivative and pharmaceutical application thereof | |
EP3950688A1 (en) | Nitrogen-containing spiro derivative as ret inhibitor | |
AU2013263763B2 (en) | Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors | |
WO2022228365A1 (en) | Derivative of six-membered heteroaromatic urea ring and application thereof | |
TW202246279A (en) | Pyrazinethiobiphenyl compounds and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201222 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220105 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20211222BHEP Ipc: A61K 31/4184 20060101ALI20211222BHEP Ipc: C07D 235/30 20060101AFI20211222BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230515 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019040228 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20231107 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20231110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231025 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240225 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240126 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231025 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231025 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231025 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240125 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231025 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231025 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 6 Effective date: 20240619 |